

Data + Perspectives: Clinical Investigators Discuss the Current and Future Role of Immunotherapy and Antibody-Drug Conjugates in Lung Cancer

Friday, May 30, 2025

11:15 AM – 12:45 PM CT (12:15 PM – 1:45 PM ET)

Faculty

Marina Chiara Garassino, MBBS

John V Heymach, MD, PhD

Professor Solange Peters, MD, PhD

Moderator

Jacob Sands, MD

Faculty



Marina Chiara Garassino, MBBS
Section of Hematology/Oncology
Professor of Medicine
Director, Thoracic Oncology Program
Department of Medicine
The University of Chicago
Chicago, Illinois



Professor Solange Peters, MD, PhD
Medical Oncology Director
Lausanne University Hospital
Lausanne, Switzerland



John V Heymach, MD, PhD
Professor and Chair
Thoracic/Head and Neck Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas



Moderator
Jacob Sands, MD
Associate Chief, Thoracic Oncology
Dana-Farber Cancer Institute
Assistant Professor
Harvard Medical School
Boston, Massachusetts

Prof Garassino — Disclosures Faculty

Advisory Committees	AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Daiichi Sankyo Inc, Gilead Sciences Inc, IO Biotech, Janssen Biotech Inc, Lilly, Merck, Mirati Therapeutics Inc, Natera Inc, Novocure Inc, Nuvation Bio, Pfizer Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines, Roche Laboratories Inc, Takeda Pharmaceuticals USA Inc
----------------------------	--

Dr Heymach — Disclosures

Faculty

Advisory Committees	AstraZeneca Pharmaceuticals LP, BerGenBio ASA, BioAtla, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Chugai Pharmaceutical Co Ltd, Curio Science, EMD Serono Inc, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Mirati Therapeutics Inc, Novartis, Regeneron Pharmaceuticals Inc, Sanofi, Spectrum Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc
Licensing/Royalties	Spectrum Pharmaceuticals Inc
Research Support	AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Mirati Therapeutics Inc, Spectrum Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc

Prof Peters — Disclosures

Faculty

Advisory Committees and Consulting Agreements (All Fees to Institution)	AbbVie Inc, Amgen Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BerGenBio ASA, Biocartis, BioInvent, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Daiichi Sankyo Inc, Debiopharm, Foundation Medicine, F-star Therapeutics Inc, Genentech, a member of the Roche Group, Genzyme Corporation, Gilead Sciences Inc, GSK, HUTCHMED, Illumina, Incyte Corporation, Ipsen Biopharmaceuticals Inc, iTeos Therapeutics, Janssen Biotech Inc, Lilly, Merck Serono, Merrimack Pharmaceuticals Inc, Mirati Therapeutics Inc, MSD, Novartis, Novocure Inc, Nykode Therapeutics, Pfizer Inc, PharmaMar, Promontory Therapeutics, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Takeda Pharmaceutical Company Limited
Contracted Research (Institutional Support)	Principal investigator for trials sponsored by Amgen Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, iTeos Therapeutics, Mirati Therapeutics Inc, MSD, PharmaMar, Promontory Therapeutics, Seagen Inc
Data and Safety Monitoring Boards/Committees	AstraZeneca Pharmaceuticals LP
Speakers Bureaus (All Fees to Institution)	AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Foundation Medicine, Genentech, a member of the Roche Group, GSK, Illumina, Ipsen Biopharmaceuticals Inc, Lilly, Mirati Therapeutics Inc, MSD, Novartis, Pfizer Inc, Sanofi, Takeda Pharmaceutical Company Limited

Dr Sands — Disclosures

Moderator

Consulting Agreements	AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Curadev, Daiichi Sankyo Inc, Fosun Pharma, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Lilly, Mariana Oncology, Medtronic Inc, Merck, Novartis, Pfizer Inc, Sanofi, Summit Therapeutics
Contracted Research	Harpoon Therapeutics, Novartis
Data and Safety Monitoring Boards/Committees	Johnson & Johnson Pharmaceuticals

Dr Love — Disclosures

Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

Commercial Support

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers

Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of non-FDA-approved uses of agents and regimens. Please refer to official prescribing information for each product for approved indications.

Agenda

Module 1: Role of Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Tumor Mutation — Prof Peters

Module 2: Targeted and Other Novel Therapeutic Strategies for Relapsed Metastatic NSCLC — Prof Garassino

Module 3: Potential Role of TROP2-Targeted Antibody-Drug Conjugates in Advanced NSCLC — Dr Sands

Module 4: Evolving Role of Immune Checkpoint Inhibitors in the Care of Patients with Nonmetastatic NSCLC — Dr Heymach


Agenda

Module 1: Role of Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Tumor Mutation — Prof Peters

Module 2: Targeted and Other Novel Therapeutic Strategies for Relapsed Metastatic NSCLC — Prof Garassino

Module 3: Potential Role of TROP2-Targeted Antibody-Drug Conjugates in Advanced NSCLC — Dr Sands

Module 4: Evolving Role of Immune Checkpoint Inhibitors in the Care of Patients with Nonmetastatic NSCLC — Dr Heymach




A Role of Immune Checkpoint Inhibitors for Metastatic NSCLC without a Targetable Tumor Mutation

Pr Solange Peters, MD-PhD

Lausanne University Hospital & Ludwig Institute
Switzerland

ICI-based 1L strategies in mNSCLC



Anti-PD1/PD-L1

Monotherapy

With chemotherapy

With anti-CTLA-4

With anti-CTLA-4 and chemotherapy

New combinations


Anti-PD(L)-1 monotherapy in 1L mNSCLC (PD-L1 $\geq 50\%$)

	Patients	PFS (months)	OS (months)	ESMO MCBS score ⁸
KEYNOTE-024 ^{1,2} (pembrolizumab vs chemo)	305	7.7 vs 5.5, HR 0.50	5 year OS 31.9%	A/5
IMpower110 ^{3,4} (atezolizumab vs chemo)	205	8.2 vs 5.0, HR 0.59	20.2 vs 14.7, HR 0.76	5
EMPOWER-Lung 1 ^{5,6,7} (cemiplimab vs chemo)	712	8.1 vs 5.3, HR 0.50	5 years OS 29%	4


1) Reck, et al. JCO. 8 Jan 2019.; 2) Brahmer J, et al. Presented at ESMO 2020. Abstract LBA51; 3) Spigel D, et al. Presented at ESMO 2019. Abstract LBA78. 4) Herbst R, et al. Presented at WCLC 2020. Abstract FP13.03. 5) Sezer A, et al. Presented at ESMO 2020. Abstract LBA52. 6) Özgüroğlu M, et al. Presented at ESMO 2022. Abstract LBA54. 7) Baramidze A, et al. Presented at WCLC 2024. Abstract OA11.06.; 8) <https://www.esmo.org/living-guidelines/esmo-non-oncogene-addicted-metastatic-non-small-cell-lung-cancer-living-guideline>, Jan, 2025

The 50% TC cut-off is validated first line in NSCLC





KEYNOTE-024




IMpower110 WT






EMPOWER-Lung 1




Clinical continuum: anti PD(L)-1 in very high PD-L1




EMPOWER-Lung 1




KEYNOTE-024: A word of caution?



- 1/3 of patients experience **progressive disease at first assessment**
- A surprisingly **small proportion of patients receive second-line therapy**
 - RWD **25%**
 - KEYNOTE-024: **53%**
 - KEYNOTE-042: **46%**
 - EMPOWER-Lung 1: **32%**



IO-based 1L strategies in mNSCLC



Anti-PD₁/PD-L₁

Monotherapy

With chemotherapy

With anti-CTLA-4

With anti-CTLA-4 and chemotherapy

New combinations

ChT ± (dual) anti-PD(L)-1 in 1L Non-Sq mNSCLC

ICI	± ChT	Patients	PFS (months)	OS (months)	ESMO MCBS score ¹²
KEYNOTE-189 ^{1,2,3,4} (pembrolizumab)	CisP/CbP + pemetrexed	616	9.0 vs 4.9, HR 0.50	5 years OS 19.4%	A/4
IMpower150 ^{5,6} (atezolizumab)	CbP-paclitaxel ± bevacizumab	697	8.3 vs 6.8, HR 0.59	19.5 vs 14.7, HR 0.80	4
IMpower130 ^{7,8} (atezolizumab)	CbP + nab-paclitaxel	723	7.0 vs 5.5, HR 0.64	18.6 vs 13.9, HR 0.79	4
EMPOWER-Lung 3 ⁹ (cemiplimab)	Platinum doublet	266*	7.9 vs 5.7, HR 0.53*	19.4 vs 12.4, HR 0.64*	4
GEMSTONE-302 ¹⁰ (sugemalimab)	CbP + pemetrexed	191*	9.6 vs 5.9, HR 0.57*	26.0 vs 19.8, HR 0.72*	4
RATIONALE-304 ¹¹ (tislelizumab)	CisP/CbP + pemetrexed	334	9.8 vs 7.6, HR 0.47	21.6 vs 20.1, HR 0.85	4 (for PD-L1 ≥50%)

* Non Sq subgroup analysis

1) Gadgeel S, et al. Presented at ASCO 2019. Abstract 9013. 2) Rodriguez-Abreu D. Presented at ASCO 2020. Abstract 9582. 3) Gray JE, et al. Presented at WCLC 2020. Abstract FP13.02. 4) Garassino M, et al. Presented at ESMO 2022. Abstract 973MO. 5) Socinski M, et al. *N Engl J Med*. 4 Jun 2018. 6) Socinski M, et al. Presented at AACR 2020. Abstract CT126. 7) Cappuzzo, et al. Presented at ESMO 2018. Abstract LBA53. 8) West HJ, et al. *Lancet*. 20 May 2019. 9) Makharadze T, et al. Presented at ELCC 2023. Abstract 5O. 10) Zhou C, et al. Presented at ESMO 2024. Abstract 1318P. 11) Lu S, et al. Presented at ESMO IO 2022. Abstract 138P. 12) <https://www.esmo.org/living-guidelines/esmo-non-oncogene-addicted-metastatic-non-small-cell-lung-cancer-living-guideline>, Jan, 2025


ChT ± (dual) anti-PD(L)-1 in 1L Sq. mNSCLC

(Dual) Anti-PD-L1	± ChT	Patients	PFS (months)	OS (months)	ESMO MCBS score ¹⁰
KEYNOTE-407 ^{1,2,3} (pembrolizumab)	CisP/CbP + paclitaxel or nab-paclitaxel	559	8.0 vs 5.1, HR 0.62	5 years OS 18.4%	4/A
EMPOWER-Lung 3 ⁴	Platinum based ChT	200*	8.2 vs 4.9, HR 0.56*	22.3 vs 13.8, HR 0.61*	4
RATIONALE-307 ^{5,6,7,8} (tislelizumab)	CbP-(nab)paclitaxel	360	7.7 vs 9.5 vs 5.5 HR 0.45 and 0.45	26.1 vs 23.3 vs 19.4 HR 0.67 and 0.82	4 (pacli), 3 (nab-pacli)
GEMSTONE-302 ⁹ (sugemalimab)	CbP + paclitaxel	192*	8.3 vs 4.8, HR 0.37*	23.6 vs 12.2, HR 0.61*	4

* Sq subgroup analysis

Chemotherapy might not be needed in PD-L1 ≥50%

Adjusted analysis (rwPFS)




CIT-combo vs CIT-mono (reference)	Hazard ratio (95% CI)	P value
Unadjusted analysis	1.01 (0.78, 1.05)	0.957
Adjusted analysis	1.04 (0.78, 1.37)	0.811

^a Proportional hazards assumption is violated in the unadjusted model (Schoenfeld residual test).

The propensity score model included metastatic type, age, race, ECOG performance status score, brain metastases, smoking status, sex, liver metastases, time to 1L treatment start.

Overall survival
Unadjusted analysis




Group	Patients	Events, n (%)	Median rwPFS (95% CI), mo
CIT-mono	351	170 (48)	11.5 (8.12, 15.01)
CIT-combo	169	87 (52)	10.8 (8.97, 15.31)

EMPOWER-Lung 3: outcomes across PD-L1 subgroups

OS

	Cemiplimab + chemo (OS events/patients)	Placebo + chemo (OS events/patients)	Hazard ratio (95% CI)
All patients	180/312	111/154	0.65 (0.51–0.82)
Age group			
<65 years	100/184	70/94	0.53 (0.39–0.72)
≥65 years	80/128	41/60	0.81 (0.55–1.18)
Sex			
Male	155/268	92/123	0.55 (0.42–0.71)
Female	25/44	19/31	0.98 (0.54–1.78)
Race			
White	155/267	102/138	0.61 (0.47–0.78)
Non-White	25/45	9/16	0.81 (0.38–1.74)
Histology			
Squamous	79/133	47/67	0.61 (0.42–0.87)
Nonsquamous	101/179	64/87	0.64 (0.47–0.88)
PD-L1 level			
<1%	66/95	34/44	0.94 (0.62–1.42)
1–49%	62/114	43/61	0.50 (0.34–0.74)
≥50%	52/103	34/49	0.56 (0.36–0.86)
ECOG performance status			
0	15/51	14/18	0.24 (0.12–0.51)
1	163/259	96/134	0.70 (0.54–0.90)
Geographic region			
Europe	157/270	102/138	0.61 (0.48–0.79)
Asia	23/42	9/16	0.78 (0.36–1.69)
Brain metastasis at baseline			
Yes	12/24	7/7	0.29 (0.11–0.75)
No	168/288	104/147	0.65 (0.51–0.83)
Cancer stage at screening			
Locally advanced	21/45	18/24	0.50 (0.27–0.95)
Metastatic	159/267	93/130	0.64 (0.49–0.83)
Smoking history			
Smokers	155/269	96/130	0.58 (0.45–0.75)
Non-smokers	25/43	15/24	0.85 (0.45–1.62)



PFS

	Cemiplimab + chemo (PFS events/patients)	Placebo + chemo (PFS events/patients)	Hazard ratio (95% CI)
All patients	234/312	133/154	0.55 (0.44–0.68)
Age group			
<65 years	134/184	84/94	0.50 (0.38–0.66)
≥65 years	100/128	49/60	0.60 (0.42–0.85)
Sex			
Male	203/268	107/123	0.48 (0.38–0.62)
Female	31/44	26/31	0.71 (0.42–1.20)
Race			
White	208/267	119/138	0.55 (0.44–0.69)
Non-White	26/45	14/16	0.53 (0.28–1.02)

H Feb 24, 2023
Kristi Rosa



The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of cemiplimab-rwlc in combination with platinum-based chemotherapy as frontline treatment for adult patients with advanced non-small cell lung cancer with PD-L1 expression of 1% or higher.




The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of cemiplimab-rwlc in combination with platinum-based chemotherapy as frontline treatment for adult patients with advanced non-small cell lung cancer (NSCLC) with PD-L1 expression of 1% or higher in the European Union.¹

The approval would include patients who are not candidates to receive definitive chemoradiation, whose tumors are metastatic or locally advanced, and who do not harbor *EGFR*, *ALK*, or *ROS1* aberrations.

The positive opinion is based on data from the phase 3 Study 16113/EMPOWER-Lung 3 trial (NCT03409614). Of the 466 patients enrolled to the trial, 327 had tumors with a PD-L1 expression of at least 1%. In this subgroup, cemiplimab plus chemotherapy (n = 217) resulted in a median overall survival (OS) of 22 months vs 13 months with chemotherapy alone (n = 110) at a median follow-up of 16 months; this translated to a 45% relative reduction in the risk of death (HR, 0.55; 95% CI, 0.39–0.78). With a longer median follow-up of 28 months, cemiplimab/chemotherapy continued to showcase a meaningful survival benefit in this group (HR, 0.51; 95% CI, 0.38–0.69).

ChT + anti-PD(L)-1: Why adding an anti-CTLA-4?





ChT, chemotherapy; PD-L1, programmed death-ligand 1.


¹Peters S. Presented at IASLC 2023 WCLC; ²Johnson ML, et al. Presented at ESMO Congress 2022; ³Paz-Ares LG, et al. Presented at ASCO 2022.

CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire

Lidia Robert¹, Jennifer Tsoi², Xiaoyan Wang^{1,3}, Ryan Emerson^{7,8}, Blanca Homet^{1,9}, Thinle Chodon¹, Stephen Mok^{1,2}, Rong Rong Huang⁴, Alistair J. Cochran⁴, Begoña Comin-Anduix^{5,6}, Richard C. Koya^{5,6}, Thomas G. Graeber^{2,6}, Harlan Robins^{7,8}, and Antoni Ribas^{1,2,5,6}

**A**Richness (pre vs. post): $P = 0.001$ Richness
(number of unique sequences)**B**Shannon diversity index (pre vs. post): $P = 0.04$

Shannon diversity index




Normalized TCR V-beta CDR3 repertoire diversity.

Analysis comparing baseline and post-tremelimumab PBMC samples, Richness and Shannon index for diversity. Differences in richness for total number of unique productive sequences ($P = 0.001$; A) and Shannon index for diversity of the repertoire ($P = 0.04$; B).


DUAL ICB +/- chemo phIII trial data

CheckMate 9LA

mPFS **6.7** vs **5.3** months
HR 0.70 (0.60-0.83)




mOS **15.8** vs **11.0** months
HR 0.73 (0.62-0.85)




POSEIDON

mPFS **6.2** vs **4.8** months
HR 0.72 (0.60-0.86)




mOS **14.0** vs **11.6** months
HR 0.76 (0.64-0.89)




CheckMate 227 PD-L1+




mPFS **5.1** vs **5.6** months
HR 0.79 (0.67-0.94)






mOS **17.1** vs **14.9** months
HR 0.77 (0.66-0.91)



CheckMate 227: adding a CTLA-4 is active in negative PD-L1



Adding a CTLA-4 improves OS in negative PD-L1 in POSEIDON



Possible mechanisms of *STK11* loss-mediated immune escape

Recruitment of

Article

CTLA4 blockade abrogates *KEAP1*/*STK11*-related resistance to PD-(L)1 inhibitors

<https://doi.org/10.1038/s41586-024-07943-7>

Received: 27 October 2023

Accepted: 13 August 2024





Published online: 09 October 2024

Open access

 Check for updates

For patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of anti-tumour activity and immune-related toxicities, when compared with treatment with PD-(L)1 inhibitors alone. However, there are currently no validated biomarkers to identify which patients will benefit from dual ICB^{1,2}. Here we show that patients with NSCLC who have mutations in the *STK11* and/or *KEAP1* tumour suppressor genes derived clinical benefit from dual ICB with the PD-L1 inhibitor durvalumab and the CTLA4 inhibitor tremelimumab, but not from durvalumab alone, when added to chemotherapy in the randomized phase III POSEIDON trial³. Unbiased genetic screens identified loss of both of these tumour suppressor genes as independent drivers of resistance to PD-(L)1 inhibition, and showed that loss of *Keap1* was the strongest genomic predictor of dual ICB efficacy—a finding that was confirmed in several mouse models of *Kras*-driven NSCLC. In both mouse models and patients, *KEAP1* and *STK11* alterations were associated with an adverse tumour microenvironment, which was characterized by a preponderance of suppressive myeloid cells and the depletion of CD8⁺ cytotoxic T cells, but relative sparing of CD4⁺ effector subsets. Dual ICB potently engaged CD4⁺ effector cells and reprogrammed the tumour myeloid cell compartment towards inducible nitric oxide synthase (iNOS)-expressing tumoricidal phenotypes that—together with CD4⁺ and CD8⁺ T cells—contributed to anti-tumour efficacy. These data support the use of chemo-immunotherapy with dual ICB to mitigate resistance to PD-(L)1 inhibition in patients with NSCLC who have *STK11* and/or *KEAP1* alterations.

Low CD3




Exploratory analyses suggest addition of a CTLA-4 might improve outcomes in biomarker-defined subgroups

POSEIDON: *STK11m* and *KRASm* sub-analyses


STK11m

	T+D+CT	D+CT	CT
Events/patients, n/N	27/31	32/34	22/22
mOS, months (95% CI)	15.0 (8.2–23.8)	6.9 (3.6–12.9)	10.7 (6.0–14.9)
HR* (95% CI)	0.57 (0.32–1.04)	1.02 (0.59–1.80)	–



KRASm

	T+D+CT	D+CT	CT
Events/patients, n/N	47/60	56/69	47/53
mOS, months (95% CI)	25.7 (9.9–36.7)	12.6 (7.5–16.9)	10.4 (7.3–12.6)
HR* (95% CI)	0.55 (0.36–0.83)	0.74 (0.50–1.09)	–




The same is seen:

- For KEAP-1 alterations
- In CheckMate 9LA and 227

TRITON: An ongoing phase III trial

TRITON

Phase IIIb randomized, open-label, multicenter study



^aDurvalumab 1500 mg Q3W + tremelimumab 75 mg Q3W + (platinum + pemetrexed 500 mg/m² Q3W); tremelimumab (permitted up to 5 cycles). ^bPembrolizumab 200 mg Q3W + (platinum + pemetrexed 500 mg/m² Q3W).


^cDurvalumab 1500 mg Q4W + tremelimumab 75 mg (one dose at week 16 only) + pemetrexed 500 mg/m² Q3W. ^dPembrolizumab 200 mg Q3W + pemetrexed 500 mg/m² Q3W.

Participants must have tumors with STK11 or KEAP1 or KRAS mutations. Co-mutations are also allowed


CheckMate 9LA: a higher magnitude of benefit if brain mets

Postohoc analysis of patients treated in CheckMate 9LA, 3 years update

3-year update




With baseline treated brain mets




Without brain mets

Ipi/nivo + 2 cycles of chemo demonstrated efficacy in patients with advanced NSCLC and CNS metastases^{1,2}

Checkmate 227



Checkmate 9LA



chemo=chemotherapy; CI=confidence interval; CNS=central nervous system; HR=hazard ratio; IPI=ipilimumab; mets=metastases; mo=month; NIVO=nivolumab; NSCLC=non-small cell lung cancer; OS=overall survival.

1. Borghaei H, et al. AACR Annual Meeting 2020. Abstract CT221 (CheckMate 227). 2. Reck M, et al. 2021 ASCO. Abstract 9000 (CheckMate 9LA).

ChT ± (dual) anti-PD(L)-1 in 1L Non-Sq mNSCLC

ICI	± ChT	Patients	PFS (months)	OS (months)	ESMO MCBS score ²¹
Keynote 189 ^{1,2,3,4} (pembrolizumab)	CisP/CbP + pemetrexed	616	9.0 vs 4.9, HR 0.50	5 years OS 19.4%	A/4
IMPower 150 ^{5,6} (atezolizumab)	CbP-paclitaxel ± bevacizumab	697	8.3 vs 6.8, HR 0.59	19.5 vs 14.7, HR 0.80	4
IMPower 130 ^{7,8} (atezolizumab)	CbP + nab-paclitaxel	723	7.0 vs 5.5, HR 0.64	18.6 vs 13.9, HR 0.79	4
EMPower-Lung-3 ⁹ (cemiplimab)	Platinum doublet	266*	7.9 vs 5.7, HR 0.53*	19.4 vs 12.4, HR 0.64*	4
Gemstone-302 ¹⁰ (sugemalimab)	CbP + pemetrexed	191*	9.6 vs 5.9, HR 0.57*	26.0 vs 19.8, HR 0.72*	4
Rationale-304 ¹¹ (tislelizumab)	CisP/CbP + pemetrexed	334	9.8 vs 7.6, HR 0.47	21.6 vs 20.1, HR 0.85	4 (for PD-L1 ≥50%)
CM-gLA ^{12,13,14} (nivolumab + ipilimumab)	2 cycles platinum + pemetrexed	492*	6.9 vs 5.6, HR 0.75*	5 year OS 19%*	4
POSEIDON ^{15,16,17} (durvalumab + tremelimumab)	4 cycles platinum doublet ChT	428*	6.8 vs 5.5, HR 0.66*	5 year OS 20.5%*	4
Check-Mate 227 ^{18,19,20} (nivo+ipi vs chemo) TPS ≥ 1%	-	557*	5.5 vs 5.9, HR 0.83*	6 year OS 25%*	4

* Non Sq subgroup analysis

1) Gadgeel S, et al. Presented at ASCO 2019. Abstract 9013. 2) Rodriguez-Abreu D. Presented at ASCO 2020. Abstract 9582. 3) Gray JE, et al. Presented at WCLC 2020. Abstract FP13.02. 4) Garassino M, et al. Presented at ESMO 2022. Abstract 973MO. 5) Socinski M, et al. *N Engl J Med*. 4 Jun 2018. 6) Socinski M, et al. Presented at AACR 2020. Abstract CT126. 7) Cappuzzo, et al. Presented at ESMO 2018. Abstract LBA53. 8) West HJ, et al. *Lancet*. 20 May 2019. 9) Makharadze T, et al. Presented at ELCC 2023. Abstract 5O. 10) Zhou C, et al. Presented at ESMO 2024. Abstract 1318P. 11) Lu S, et al. Presented at ESMO IO 2022. Abstract 138P. 12) Paz-Ares L, et al. Presented at ASCO 2022. Abstract LBA9026. 13) Carbone D, et al. Presented at ASCO 2023. Abstract LBA9023. 14) Reck M, et al. Presented at ASCO 2022. Abstract 856O. 15) Johnson M, et al. Presented at ESMO 2022. Abstract LBA59. 16) Johnson M, et al. *JTO* 2023. 3 Nov 2022. 17) Peters S, et al. Presented at ESMO IO 2023. Abstract LBA3. 18) Paz-Ares, et al. *JTO*. 20 Sept 2021. 19) Brahmer J, et al. Presented at ASCO 2022. Abstract LBA9025. 20) Peters S, et al. Presented at WCLC 2023. Abstract OA14.03; 21) <https://www.esmo.org/living-guidelines/esmo-non-oncogene-addicted-metastatic-non-small-cell-lung-cancer-living-guideline>, Jan, 2025



ChT ± (dual) anti-PD(L)-1 in 1L Sq. mNSCLC

(Dual) Anti-PD-L1	± ChT	Patients	PFS (months)	OS (months)	ESMO MCBS score ¹⁹
Keynote 407 ^{1,2,3} (pembrolizumab)	CisP/CbP + paclitaxel or nab-paclitaxel	559	8.0 vs 5.1, HR 0.62	5 years OS 18.4%	4/A
Empower-Lung 3 ⁴	Platinum based ChT	200*	8.2 vs 4.9, HR 0.56*	22.3 vs 13.8, HR 0.61*	4
Rationale-307 ^{5,6,7,8} (tislelizumab)	CbP-(nab)paclitaxel	360	7.7 vs 9.5 vs 5.5 HR 0.45 and 0.45	26.1 vs 23.3 vs 19.4 HR 0.67 and 0.82	4 (pacli), 3 (nab-pacli)
Gemstone-302 ⁹ (sugemalimab)	CbP + paclitaxel	192*	8.3 vs 4.8, HR 0.37*	23.6 vs 12.2, HR 0.61*	4
CM-gLA ^{10,11,12} (nivolumab + ipilimumab)	2 cycles platinum + paclitaxel or pemetrexed	227*	5.6 vs 4.3 HR 0.65*	5 years OS 18%*	4
POSEIDON ^{13,14,15} (durvalumab + tremelimumab)	4 cycles platinum doublet ChT	246*	4.6 vs 4.6, HR 0.68*	5 years OS 7.3%*	4
Check-Mate 227 ^{16,17,18} (nivo+ipi vs chemo) TPS ≥ 1%	-	236*	4.1 vs 4.3, HR 0.77*	6 year OS 14%*	4


* Sq subgroup analysis

1) Paz-Ares L, et al. Presented at ESMO 2019. Abstract LBA82. 2) Robinson A, et al. Presented at ELCC 2021. Abstract 970. 3) Novello S, et al. Presented at ESMO 2022. Abstract 974MO. 4) Makharadze T, et al. Presented at ELCC 2023. Abstract 50. 5) Wang J, et al. Presented at Chinese Society of Clinical Oncology Congress 2020. 6) Wang J, et al. JAMA Oncol. 2021;7:709. 7) Wang J, et al. Presented at ESMO IO 2022. Abstract 132P. 8) Wang Z, et al. Presented at ESMO 2024. Abstract 1323P. 9) Zhou C, et al. Presented at ESMO 2024. Abstract 1318P. 10) Paz-Ares L, et al. Presented at ASCO 2022. Abstract LBA9026. 11) Carbone D, et al. Presented at ASCO 2023. Abstract LBA9023. 12) Reck M, et al. Presented at ASCO 2024. Abstract 8560. 13) Johnson M, et al. Presented at ESMO 2022. Abstract LBA59. 14) Johnson M, et al. JTO 2023. 3 Nov 2022. 15) Peters S, et al. Presented at ESMO IO 2023. Abstract LBA3. 16) Paz-Ares, et al. JTO. 20 Sept 2021. 17) Brahmer J, et al. Presented at ASCO 2022. Abstract LBA9025. 18) Peters S, et al. Presented at WCLC 2023. Abstract OA14.03; 19) <https://www.esmo.org/living-guidelines/esmo-non-oncogene-addicted-metastatic-non-small-cell-lung-cancer-living-guideline>, Jan, 2025

ESMO CPG: some nuances



Bispecific Antibodies under Investigation in Lung



Ongoing Phase III Trials Investigating Immune Checkpoint Bispecific Antibodies

Trial	Phase	Bispecific Antibody (targets)	Eligibility	Intervention	Primary Endpoint	Interim Results
HARMONI-7 (NCT06767514)	III	Ivonescimab (PD-1 and VEGF)	First-line metastatic NSCLC with PD-L1 expression (TPS ≥50%)	Ivonescimab v pembrolizumab	PFS, OS	
HARMONI (NCT06396065)	III	Ivonescimab (PD-1 and VEGF)	EGFR-mutant locally advanced or metastatic NSCLC that has progressed on EGFR inhibitor	Ivonescimab (SMT112/AK112) + pemetrexed + carboplatin v placebo + pemetrexed + carboplatin	PFS, OS	
HARMONI-3 (NCT05899608)	III	Ivonescimab (PD-1 and VEGF)	First-line metastatic NSCLC	Ivonescimab + chemotherapy v pembrolizumab + chemotherapy	PFS, OS	
NCT06020352	II/III	KN046 (PD-1 and CTLA-4)	Neoadjuvant therapy for resectable stage IB to IIIB NSCLC	KN046 + axitinib followed by surgery	MPR and surgical resection rate	
NCT05756972	II/III	PM8002 (PD-1 and VEGF-A)	EGFR-mutant locally advanced or metastatic nonsquamous NSCLC who have failed EGFR-TKI treatment	PM8002 + chemotherapy v chemotherapy alone	ORR, PFS	ORR was 54.7% (35/64, 95% CI, 41.8 to 67.2) and DCR was 95.3% (61/64, 95% CI, 86.9 to 99.0) ⁶²
ABBILITY NSCLC-06 (NCT06635824)	III	Acasunlimab (PD-1 and 4-1BB)	PD-L1–positive metastatic NSCLC who have been treated with PD-1/PD-L1 inhibitor and platinum-containing chemotherapy, administered either in combination or sequentially in the metastatic setting	Acasunlimab + pembrolizumab v docetaxel	OS	
NCT06617416	III	Cadonilimab (PD-1 and CTLA-4)	Unresectable locally advanced NSCLC	Cadonilimab v sugemalimab	PFS	
ARTEMIDE-Lung02 (NCT06692738)	III	Rilvegostomig (PD-1 and TIGIT)	First-line treatment of squamous metastatic NSCLC with PD-L1 ≥1%	Rilvegostomig v pembrolizumab, both in combination with platinum-based doublet chemotherapy	PFS, OS	
ARTEMIDE-Lung04 (NCT06868277)	III	Rilvegostomig (PD-1 and TIGIT)	First-line treatment of PD-L1–high metastatic NSCLC	Rilvegostomig v pembrolizumab	PFS, OS	



Faculty Case Presentations

Case Presentation – Dr Sands: Metastatic lung adenocarcinoma

- 69 yr old man experienced worsening shortness of breath over 3 months leading to presentation to PCP. Diagnosed with pneumonia and treated without improvement.
- Referred to cardiology and pulmonology. Diagnosed with restrictive/obstructive disease and prescribed steroids and albuterol inhaler with some relief.
- About 1 month later, presented to PCP with worsening symptoms. CT scan showed bilateral pulmonary emboli, extensive infiltrates, “mass-like features”, and adenopathy. Wife drove him to BWH for worsening symptoms where he was admitted.
- Lung adenocarcinoma diagnosed from EBUS nodes and pericardial fluid. No actionable alterations. PD-L1 = 20%



Case Presentation – Dr Sands: Metastatic lung adenocarcinoma (cont'd)

- 1L treatment: carboplatin, pemetrexed, and pembrolizumab and had partial response with total ~10 months disease control
- 2L treatment: Initiated DS-1062 (Dato-DXd) on clinical trial
- Tolerated treatment well with only significant toxicity being ocular. He did not like using eye drops and did not consistently start using until being told that if symptoms worsened, he might have to stop the treatment.



Case Presentation – Dr Sands: Metastatic lung adenocarcinoma (cont'd)

- These scans show baseline to 9 months into treatment with a 72% reduction in measurable tumor volume.
- Had partial response with disease control for ~21 months
- At progression, he was treated on docetaxel as next line therapy with early progression and then with gemcitabine with brief disease control.



Questions for the Faculty

Do you view pembrolizumab, atezolizumab and cemiplimab monotherapy as equivalent options for patients with a PD-L1 TPS $\geq 50\%$? Do you have a preference for a particular agent for patients with nonsquamous or squamous disease?

In which situations, if any, are you currently recommending anti-PD-1/PD-L1 monotherapy for patients with a PD-L1 TPS $< 50\%$?

Questions for the Faculty

**In which situations are you currently recommending an anti-PD-1/
PD-L1 antibody in combination with chemotherapy for patients with
a PD-L1 TPS $\geq 50\%$?**

**How do you think through therapeutic selection after disease
progression on first-line chemoimmunotherapy? Would you ever
rechallenge with an alternative immune checkpoint inhibitor-
containing regimen?**

Questions for the Faculty

Do you believe immune checkpoint bispecific antibodies will replace anti-PD-1/PD-L1 antibodies as first-line treatment?

Which particular immune checkpoint bispecific antibodies (PD-1 x VEGF, PD-1 x CTLA-4, PD-1 x TIGIT), if any, are you particularly enthusiastic about?

Which ongoing trials evaluating novel immune checkpoint bispecific antibodies are you recommending for your patients?

Questions for the Faculty

In which situations are you currently recommending an anti-PD-1/PD-L1 antibody in combination with an anti-CTLA-4 antibody as first-line treatment for metastatic NSCLC? What about an anti-PD-1/PD-L1 antibody in combination with an anti-CTLA-4 antibody and chemotherapy?

Do you believe these regimens might be preferential in patients with PD-L1-negative disease? What about in those with symptomatic, high tumor-volume disease? What about in patients with CNS involvement?

Questions for the Faculty

Beyond negative PD-L1, are there any biomarkers (eg, STK11/KEAP1 mutations, KRAS mutations) that would make you more inclined to favor an anti-PD-1/PD-L1 antibody in combination with an anti-CTLA-4 antibody with or without chemotherapy as first-line therapy?

Should community-based oncologists be testing for STK11/KEAP1 mutations in their patients with metastatic NSCLC and considering them when making decisions regarding first-line therapy?

Agenda

Module 1: Role of Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Tumor Mutation — Prof Peters

Module 2: Targeted and Other Novel Therapeutic Strategies for Relapsed Metastatic NSCLC — Prof Garassino

Module 3: Potential Role of TROP2-Targeted Antibody-Drug Conjugates in Advanced NSCLC — Dr Sands

Module 4: Evolving Role of Immune Checkpoint Inhibitors in the Care of Patients with Nonmetastatic NSCLC — Dr Heymach

Targeted and Other Novel Therapeutic Strategies for Relapsed Metastatic NSCLC

Marina Chiara GARASSINO

Professor of Medicine

Director, Thoracic Oncology Program

University of Chicago

Two new targets


- HER2
- c-Met

HER2

Select Phase 2 Trials in *HER2*-Altered NSCLC



Drug	Phase	N	RR, %	PFS, mo
TKIs				
Afatinib	2	13	7.7	4
Dacomitinib	2	30	11.5	3
Poziotinib	2	12	50	5.6
Pyrotinib	2	15	53.3	6.4
Monoclonal antibodies/ADCs				
Ado-trastuzumab emtansine	2	18	44	5.0
Trastuzumab deruxtecan	2	42	61	14

Trastuzumab Deruxtecan (T-DXd)



Conjugation Chemistry

The linker is connected to cysteine residue of the antibody



- ADC composed of three components
 - Humanized HER2-targeted mAb
 - Topoisomerase I inhibitor “payload”
 - Tetrapeptide-based cleavable linker

- High drug-to-antibody ratio (~8:1)
- High potency payload that is membrane permeable → nearby cells in tumor targeted regardless of HER2 expression (“bystander antitumor effect”)

DESTINY-Lung01: Study Design

- Unresectable/metastatic nonsquamous NSCLC
- Relapsed/refractory to standard treatment
- Measurable disease by RECIST v1.1
- Asymptomatic CNS metastases at baseline^a
- ECOG PS 0 or 1
- Locally reported *HER2* mutation (cohort 2)^b

Cohort 1^c (n = 49)
HER2 overexpressing
(IHC 3+ or IHC 2+)
T-DXd 6.4 mg/kg Q3W

Cohort 1a^c (n = 41)
HER2 overexpressing
(IHC 3+ or IHC 2+)
T-DXd 5.4 mg/kg Q3W

Cohort 2 (n = 42)
HER2 mutated
T-DXd 6.4 mg/kg Q3W

Cohort 2 (n = 49)
HER2 mutated
T-DXd 6.4 mg/kg Q3W


- **Primary endpoint:** confirmed ORR by ICR^d
- **Secondary endpoints:** DOR, PFS, OS, DCR, and safety
- **Exploratory endpoint:** biomarkers of response

DESTINY-Lung01 Cohort 2 (*HER2*-Mutated NSCLC): Updated Efficacy Results

Updated data: 7 mo additional follow-up

- 1. Confirmed ORR by ICR in overall population:
54.9% (95% CI, 44.2%-65.4%)
- 2. Confirmed ORR by ICR similar across subgroups (54.5% [95% CI, 36.4%-71.9%] and 55.2% [95% CI, 41.5%-68.3%] in pts with/without CNS metastases; 55.7% [95% CI, 42.5%-68.5%] in pts with ≤2 prior lines of therapy and 53.3% [95% CI, 34.3%-71.1%] in pts with >2 prior lines)
- 3. **Median DOR in overall population: 10.6 mo**
- 4. Median DOR in pts with/without CNS metastases at baseline: 7.2 mo (95% CI, 5.3-11.1 mo)/14.7 mo (95% CI, 5.7 mo-NE)
- 5. Median DOR 14.1 mo (95% CI, 5.9-NE mo) with ≤2 prior lines of therapy vs 5.8 mo (95% CI, 4.2-12.0 mo) with >2 prior lines

Best Percentage Change From Baseline in Target Lesions by ICR for the Overall NSCLC *HER2*m Population (DCO December 3, 2021)



DESTINY-Lung01 Cohort 2 (*HER2*-Mutated NSCLC): Updated Safety Results

Safety Summary of T-DXd in the Overall *HER2*mut NSCLC Population (DCO December 3, 2021)

n, %	Overall Population (N = 91)
Any-grade TEAEs	91 (100)
Drug-related TEAEs	88 (96.7)
Drug-related grade ≥3 TEAEs	42 (46.2)
Serious drug-related TEAEs	18 (19.8)
Drug-related TEAEs associated with	
Drug discontinuation	24 (26.4)
Dose reduction	33 (36.3)
Drug interruption	31 (34.1)
Drug-related TEAEs associated with an outcome of death	2 (2.2)

Adjudicated Drug-Related ILD in the Overall *HER2*mut NSCLC Population (DCO December 3, 2021)

	Overall Population (N = 91)
Any grade, n (%)	25 (27.5)
Grade 1	3 (3.3)
Grade 2	16 (17.6)
Grade 3	4 (4.4)
Grade 4	0
Grade 5	2 (2.2)
Median time to first onset, days (range)	125 (14-461)
Median duration, days (95% CI)	43 (29-94)
Outcome of event as reported by investigator, n (%)	
Fatal	1 (4)
Not recovered/not resolved	8 (32)
Recovering/resolved	1 (4)
Recovered/resolved with sequelae	2 (8)
Recovered/resolved	13 (52)

DESTINY-Lung02: Study Design

A Blinded, Randomized, Multicenter, International, Noncomparative, Phase 2 Trial (NCT04644237)


Background

- T-DXd 5.4 mg/kg and 6.4 mg/kg showed robust antitumor activity in multiple cancer types; however, T-DXd 5.4 mg/kg has not been evaluated in patients with previously treated *HER2*mut mNSCLC
- DESTINY-Lung02 assessed the efficacy and safety of T-DXd 5.4 mg/kg and 6.4 mg/kg in patients with *HER2*mut mNSCLC
 - In the interim analysis, T-DXd showed deep and durable responses and an acceptable and generally manageable safety profile³
- Following are the **primary analysis results** of DESTINY-Lung02

Statistical considerations

- Statistical hypothesis testing for the primary analysis was performed by comparing the lower limit of the 95% Clopper–Pearson CI of confirmed ORR of a T-DXd dose with a benchmark ORR of 26.4% (upper limit of the ORR 95% CI in the ramucirumab plus docetaxel arm of the REVEL trial)⁴
- The study was not powered to statistically compare between arms

Study Design



DESTINY-Lung02: Baseline Characteristics and Efficacy Summary

Baseline characteristics


In the T-DXd 5.4 mg/kg and 6.4 mg/kg arms, respectively

- Median age was 59.4 y (range, 31-84) and 61.3 y (range 28-86)
- Most patients were female (63.7% and 68.0%), from Asia (61.8% and 60.0%), had never smoked (53.9% and 58.0%), and received prior anti-PD-(L)1 therapy (73.5% and 78.0%)
- *HER2* mutations were primarily in the kinase domain (97.1% and 100%)
- Baseline CNS metastasis was present in 34.3% and 44.0% of patients
- Median prior lines of treatment was 2 (range, 1-12) and 2 (range, 1-7)

Table 2. Summary of Efficacy Results of T-DXd		
	T-DXd 5.4 mg/kg n = 102	T-DXd 6.4 mg/kg n = 50
cORR, ^{a,b} n (%) [95% CI]	51 (50.0 [39.9-60.1])	28 (56.0 [41.3-70.0])
CR	3 (2.9)	4 (8.0)
PR	48 (47.1)	24 (48.0)
SD	44 (43.1)	18 (36.0)
PD	4 (3.9)	2 (4.0)
Non-evaluable	3 (2.9)	2 (4.0)
DCR, ^c n (%) [95% CI]	95 (93.1 [86.4-97.2])	46 (92.0 [80.8-97.8])
DoR, ^b median (95% CI), months	12.6 (6.4 to NE)	12.2 (7.0 to NE)


PFS

Figure 3. Kaplan-Meier Plot of PFS by BICR in the T-DXd 5.4 mg/kg and 6.4 mg/kg Arms




OS

Figure 4. Kaplan-Meier Plot of OS in the T-DXd 5.4 mg/kg and 6.4 mg/kg Arms




DESTINY-Lung02: Best Percentage Change in Tumor Size by BICR With T-DXd 5.4 mg/kg (N = 102)



Responses were observed regardless of *HER2* mutation type, *HER2* amplification status, and number or type of prior therapies

DESTINY-Lung02: Overall Safety Summary

Overall Safety



Adjudicated Drug-Related ILD

Adjudicated as Drug-Related ILD	T-DXd 5.4 mg/kg (n = 101 ^a)	T-DXd 6.4 mg/kg (n = 50 ^a)
Any grade, n (%)	13 (12.9)	14 (28)
Grade 1	4 (4)	4 (8)
Grade 2	7 (6.9)	9 (18)
Grade 3	1 (1)	0
Grade 4	0	0
Grade 5	1 (1)	1 (2)

- **Median treatment duration** was 7.7 mo (range, 0.7-20.8) with T-DXd 5.4 mg/kg and 8.3 mo (range, 0.7-20.3) with T-DXd 6.4 mg/kg
- The **most common any-grade TEAEs** in the T-DXd 5.4 mg/kg and 6.4 mg/kg arms included **nausea** (67.3% and 82.0%), **neutropenia** (42.6% and 56.0%), and **fatigue** (44.6% and 50.0%)
- The **most common grade ≥3 TEAEs** in the T-DXd 5.4 mg/kg and 6.4 mg/kg arms included **neutropenia** (18.8% and 36.0%) and **anemia** (10.9% and 16.0%)

Exploratory Pooled Brain Metastases Analyses of DESTINY-Lung01 and DESTINY-Lung02

DESTINY-Lung01^a

- Unresectable/metastatic nonsquamous NSCLC
- Relapsed from or is refractory to standard treatment
- Measurable disease by RECIST v1.1
- ECOG PS of 0 or 1
- Locally reported *HER2*mut (cohort 2)
- Asymptomatic BM allowed^c

Cohort 1: *HER2*-OE
(IHC 3+ or IHC 2+)
T-DXd 6.4 mg/kg Q3W
n = 49

Cohort 1a: *HER2*-OE
(IHC 3+ or IHC 2+)
T-DXd 5.4 mg/kg Q3W
n = 41

Cohort 2: *HER2*mut
T-DXd 6.4 mg/kg Q3W
n = 42

Cohort 2 expansion:
*HER2*mut
T-DXd 6.4 mg/kg Q3W
n = 49

T-DXd 5.4 mg/kg
DL-02
BM (n = 32)
Non-BM (n = 70)

DESTINY-Lung02^b

- Metastatic *HER2*m NSCLC
- ≥1 prior anticancer therapy (2L+), including platinum-based chemotherapy
- Measurable disease by RECIST v1.1
- ECOG PS of 0 or 1
- Locally reported *HER2*mut
- Asymptomatic BM allowed^c

2:1

R

T-DXd
5.4 mg/kg Q3W
n = 102

T-DXd
6.4 mg/kg Q3W
n = 50

Pooled T-DXd 6.4 mg/kg
DL-01 *HER2*mut/DL-02
BM (n = 54)
Non-BM (n = 87)

Endpoints

In patients with and without baseline BM

- Systemic cORR per BICR
- Systemic DOR per BICR
- Sites of progression per BICR
- TEAEs

In patients with measurable baseline BM^d


- IC-cORR per BICR
- IC-DCR per BICR
- IC-DOR per BICR

DESTINY-Lung01 and DESTINY-Lung02: IC Objective Response Rates and Best Overall Response (BICR)

Measurable BM at Baseline

	T-DXd 5.4 mg/kg DL-02 BM n = 14	Pooled T-DXd 6.4 mg/kg DL-01 <i>HER2m</i> /DL-02 BM n = 30
IC-cORR, n (%)^a	7 (50)	9 (30)
95% CI ^b	23-77	14.7-49.4
CR	3 (21.4)	0
PR	4 (28.6)	9 (30)
SD	6 (42.9)	13 (43.3)
PD	1 (7.1)	4 (13.3)
NE ^c	0	2 (6.7)
Missing	0	2 (6.7)
IC-DCR, n (%)^a	13 (92.9)	22 (73.3)
95% CI ^b	66.1-99.8	54.1-87.7
IC-DOR, mo^d		
Median (95% CI) ^e	9.5 (3.6-NE)	4.4 (2.9-10.2)

12/14 (86%) patients with measurable BM receiving T-DXd 5.4 mg/kg and 21/27 (78%) in the pooled 6.4 mg/kg group experienced a reduction in brain lesion size from baseline as their best overall response



^a Denominator for percentage is the number of patients in the full analysis set who have at least 1 target lesion at baseline per BICR. ^b Based on the Clopper–Pearson method for single proportion. ^c For 1 patient deemed NE in the 6.4 mg/kg group, it was not possible to derive objective response due to missing data of 1 target lesion; the patient's best overall response however was calculated from available target lesion assessments and included in the waterfall plot. ^d Calculated as time from first response in brain until progression in brain. ^e Based on Kaplan–Meier analysis and computed with the Brookmeyer–Crowley method.

DESTINY-Lung03: T-DXd Monotherapy in Pretreated HER2-overexpressing NSCLC

Patient population

- Aged ≥18 years
- Centrally assessed HER2-OE (IHC 3+/2+)* unresectable, locally advanced or metastatic nonsquamous NSCLC
- Measurable disease per RECIST v1.1
- WHO/ECOG performance status 0–1
- Patients in Part 1 had one or two prior lines of therapy; those with therapy-targetable alterations must have had prior appropriate targeted therapy

Part 1: dose escalation[†] (enrollment complete)

Arm 1A: T-DXd + durvalumab + cisplatin
Arm 1B: T-DXd + durvalumab + carboplatin

Part 1: T-DXd monotherapy (enrollment complete)

Arm 1D: T-DXd 5.4 mg/kg IV Q3W (N=36)

Part 3: dose confirmation and expansion (currently recruiting)

T-DXd + volrustomig ± carboplatin

Part 4: safety run-in and expansion (currently recruiting)

T-DXd + rilvegostomig ± carboplatin

Key endpoints: T-DXd monotherapy (arm 1D)

Secondary:


- ORR
 - DOR
 - DCR
 - PFS
 - OS
 - Safety and tolerability
- Investigator assessed

Exploratory:

- Efficacy outcomes by:
 - HER2 IHC status
 - Prior EGFR TKI exposure[‡]

DESTINY-Lung03: T-DXd Monotherapy in Pretreated HER2-overexpressing NSCLC

Part 1: T-DXd monotherapy (arm 1D; N=36)*



DESTINY-Lung04: Study Design


Patient population (N≈264)

- Unresectable, locally advanced (not amenable to curative therapy), or metastatic nonsquamous NSCLC with *HER2* exon 19 or 20 mutations^a
- Naive to systemic therapy in the locally advanced or metastatic setting
- No known other targetable oncogenic mutations/alterations

^a *HER2* mutations may be detected in tissue or ctDNA.




^b Crossover is not permitted.

^c Investigator's choice of cisplatin or carboplatin.



c-Met

c-Met overexpression, MET ex 14 mutations and MET amplification

	Alteration	NSCLC Prevalence	Biological Effects	Test		
	c-Met Overexpression¹ -3	~25% (NSQ EGFRwt)	✓ Increased c-Met expression ✓ May result from other <i>MET</i> alterations (e.g., <i>MET</i>ex14 or <i>MET</i> amplification) - X Not <u>always</u> an indicator of <i>MET</i> oncogenic dependency	IHC	Teliso-V (in development)⁵	<u>Target Domain:</u> Extracellular ⁴ <u>MOA:</u> Toxin introduction to c-Met-expressing cells; Downregulation of signaling pathway also occurs, but cell death is not dependent on signal addiction ⁴
	<i>MET</i> Mutations^{1,4} (e.g., <i>MET</i> ex14)	2-4%	✓ Reduced c-Met degradation, which may lead to c-Met expression ✓ Oncogenic signaling ✓ <i>MET</i> dependency	NGS PCR	Approved <i>MET</i> TKI (e.g., capmatinib, tepotinib)⁶	<u>Target Domain:</u> Intracellular ⁴ <u>MOA:</u> Anti-tumor activity in tumors dependent on or addicted to c-Met signaling ⁴
	<i>MET</i> Amplification^{1,4}	2-5%	✓ Increased c-Met expression ✓ Extended signaling ✓ <i>MET</i> dependency	NGS PCR FISH	<i>MET</i> TKI per NCCN Guidelines⁶	

FISH, fluorescence in situ hybridization; NGS, next generation sequencing; NCCN, National Comprehensive Cancer Network; PCR, polymerase chain reaction; TKI, tyrosine kinase inhibitor.

1. Van Der Steen N, et al. *Cancers*. 2015;7, 556-573. 2. Lee et al. *Expert Opin Ther Targets*.2021;25(4):249-268. 3. Ansell PJ, et al. CRUK Lung Cancer Conference. Nov 15-17, 2022. Manchester. 4. Liang H, Wang M. *Onco Targets Ther* 2020; 13:2491–2510; 5. Wang J, et al. *BMC Cancer*.2016; 16:105. 6. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V5.2023. ©2023 National Comprehensive Cancer Network, Inc. All rights reserved.

MET as a negative prognostic factor

Archived tissue samples from patients with NSQ NSCLC at Caris Life Sciences™ and linked patient data from ConcertAI Real World Data 360® database were used to determine clinical outcomes among patients with 1L therapy and c-Met OE.


1L TTNT-D: Unadjusted and Adjusted KM Analysis by c-Met OE Status

	n	Events	Median	95% LCL	95% UCL
Unadjusted					
c-Met high OE	23	17	2.9	2.6	9.0
c-Met OE	27	19	3.0	2.6	9.0
c-Met low/no OE	124	71	4.2	3.3	6.1
Adjusted*					
c-Met high OE	17	14	2.9	2.6	10.9
c-Met OE	21	16	4.8	2.6	9.3
c-Met low/no OE	17	9	6.4	5.9	12.0

*Doubly robust multivariable Cox proportional hazard models considering propensity score weighting and adjustment of potential confounders were used to determine the association between c-Met IHC results and TTNT-D. The multivariate regression was adjusted for the following covariates: 1L regimen, PD-L1 status, ECOG at 1L initiation, age at 1L initiation, race, biological sex, smoking status, and presence of brain metastasis at 1L initiation.



1L TTNT-D: Adjusted KM Analysis by c-Met OE Status*




Patients at Risk:

c-Met low/no OE	17	11	7	4	2	0	0	0
c-Met high OE	17	7	5	2	1	1	1	0

1L=first line; ECOG=Eastern Cooperative Oncology Group; IHC=immunohistochemistry; KM=Kaplan-Meier; LCL=lower confidence limit; NSCLC=non-small cell lung cancer; NSQ=non-squamous; OE=overexpression; PD-L1=programmed death-ligand 1; PFS=progression-free survival; TTNT-D=time to next treatment or death; UCL=upper confidence limit. 1. Le X, et al. METPRO: Evaluating prognostic value of c-Met protein overexpression and concurrent biomarker presence. Poster presented at: 2024 European Society for Medical Oncology (ESMO), 13–17 September, 2024; Barcelona, Spain [Ref DV-012467].

Poor Patient Prognosis by c-Met Overexpression

Product-Limit Survival Estimates
With Number of Patients at Risk and 95% CIs



The unadjusted hazard ratio for death in patients with NSCLC and c-Met OE vs low/no c-Met OE was 2.04 (95% CI: 1.02, 4.10)




- Samples collected in 2016 or later. Patients receiving targeted therapy as first-line treatment were excluded. [†]Patients censored at clinical trial enrollment, last follow-up or development of a new primary lung cancer, whichever occurred first. CI=confidence interval; EGFR=epidermal growth factor receptor; NSCLC=non-small cell lung cancer; NSQ=non-squamous; OE=overexpression; SOC=standard of care; WT=wildtype. **1.** Bar J, et al. Prevalence, molecular characterization, and prognosis of MET-overexpressing non-small cell lung cancer (NSCLC) in a real-world patient cohort. Poster presented at: European Society for Medical Oncology (ESMO) 2023 Annual Congress, 20–24 October 2023, Madrid, Spain, and Online.

Negative Prognostic Impact of Elevated c-Met Protein Expression in NSCLC

- A study of 5516 patients with surgically resected NSCLC found that increased c-Met protein expression was significantly associated with poor OS^{2*}
- Other meta-analyses have supported these findings and observed that increased c-Met expression was a prognostic indicator of shorter OS in patients with surgically resected stage IV NSCLC^{3,4*}



Overall Survival in Patients with High vs Low c-Met Expression^{2*}



- *Expression cutoffs varied across studies. CI=confidence interval; NSCLC=non-small cell lung cancer; OS=overall survival. **1.** Strickler JH, et al. *J Clin Oncol.* 2018;36(33):3298-3306. **2.** Guo B, et al. *PLoS One.* 2014;9(6):e99399. **3.** Ma G, et al. *Front Oncol.* 2019;9:1441. **4.** Pyo JS, et al. *Pathol Res Pract.* 2016;212(8):710-716.

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Overexpressing Advanced Non-Small Cell Lung Cancer

D. Ross Camidge¹, Jair Bar², Hidehito Horinouchi³, Jonathan Goldman⁴, Fedor Moiseenko⁵, Elena Filippova⁶, Irfan Cicin⁷, Penelope Bradbury⁸, Nathalie Daaboul⁹, Pascale Tomasini¹⁰, Tudor Ciuleanu¹¹, David Planchard¹², Mor Moskovitz-Mutsafy¹³, Nicolas Girard¹⁴, Janet Jin¹⁵, Martin Dunbar¹⁵, Ellen Bolotin¹⁵, Jim Looman¹⁵, Christine Ratajczak¹⁵, Shun Lu¹⁶

¹University of Colorado Cancer Center, Aurora, CO, USA; ²Sheba Medical Center, Ramat Gan, Israel; ³National Cancer Center Hospital, Tokyo, Japan; ⁴David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; ⁵St. Petersburg City Cancer Center, St. Petersburg, Russia; ⁶Center of Palliative Medicine De Vita, St. Petersburg, Russia; ⁷Trakya University Medical Center, Edirne, Turkey; ⁸Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; ⁹CICM, Charles-LeMoyne Hospital, University of Sherbrooke, Quebec, QC, Canada; ¹⁰Aix Marseille University, APHM, INSERM, CNRS, CRCM, Hôpital Nord, Multidisciplinary Oncology and Therapeutic Innovations Department, Marseille, France; ¹¹Institutul Oncologic, Cluj-Napoca, Romania; ¹²Medical Oncology Department, Thoracic Group, Gustave Roussy, Villejuif, France; ¹³Rambam Health Care Campus, Haifa, Israel; ¹⁴Département d'Oncologie Médicale, Institut Curie, Paris, France; ¹⁵AbbVie Inc, North Chicago, IL, USA; ¹⁶Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai, China.

American Society of Clinical Oncology (ASCO) Annual Meeting, June 3–7, 2022, Chicago, IL, USA, and Online

Telisotuzumab Vedotin (ABBV-399)

Structure:



- ✓ Antagonist **anti-c-Met antibody** (ABT-700) **linked to cytotoxin** monomethyl auristatin E (MMAE) through a cleavable linker (VC), with an average drug:antibody ratio of approximately 3.1

Target: c-Met

- ✓ Cell surface tyrosine kinase receptor that provides pro-survival and proliferation signaling
- ✓ Overexpressed in high proportion of select tumor types (NSCLC, H&N, gastric, esophageal)

Mechanism of Action:

- ✓ Targeted delivery of cytotoxin MMAE to cells via c-Met binding



c-Met

- c-Met protein overexpression (clinical trial assay for MET [SP44]) was defined as $\geq 25\%$ tumor cells with 3+ staining intensity
 - c-Met high: $\geq 50\%$, 3+
 - c-Met intermediate: $\geq 25\%$ to $< 50\%$, 3+




Study Design and Patient Characteristics

Objective: To identify the target c-Met OE NSCLC population(s) best suited for Teliso-V monotherapy in the 2L/3L setting, and then to expand the selected population(s) to further evaluate efficacy

Patient population: Patients with previously treated c-Met OE advanced/metastatic NSCLC

LUMINOSITY (Study M14-239) Design



*c-Met overexpression was defined for the NSQ cohort as $\geq 25\%$ tumor cells at 3+ intensity (high, $\geq 50\%$ 3+; intermediate, 25 to $<50\%$ 3+), and for the SQ cohort as $\geq 75\%$ of tumor cells at 1+ intensity. EGFR, epidermal growth factor receptor; MU, mutant; NSQ, non-squamous; Q2W, every 2 weeks; Teliso-V, telisotuzumab vedotin; WT, wild-type.

- As of May 27, 2021, 136 patients with c-Met OE NSCLC were treated with Teliso-V; 130 were efficacy evaluable, of whom 122 patients had ≥ 12 weeks of follow-up (or had progressed or died before the first post-baseline assessment) and were evaluable for ORR

Patient Demographics and Clinical Characteristics


Characteristic	NSQ EGFR WT N=58	NSQ EGFR MU N=44	SQ N=28
Age, median [range]	64 [33, 81]	61.5 [36, 81]	66 [45, 76]
Sex			
Male, n (%)	41 (71)	19 (43)	17 (61)
ECOG performance status, n (%)			
0	11 (19)	15 (34)	4 (14)
1	46 (79)	29 (66)	24 (86)
2	1 (2)	0	0
Stage IV at study entry, n (%)	55 (95)	42 (95)	19 (68)
Number of prior systemic cancer therapies, median [range]	1 [1, 3]	2 [1, 4]	1.5 [1, 4]
Prior systemic cancer therapies, n (%)			
Microtubule inhibitor	19 (33)	4 (9)	22 (79)
EGFR TKI	0	43 (98)	1 (4)
Platinum based	56 (97)	38 (86)	28 (100)
Immune checkpoint inhibitor based	43 (74)	8 (18)	26 (93)
Platinum and immune checkpoint inhibitor based	42 (72)	8 (18)	26 (93)
c-Met inhibitor	4 (7)	0	0

ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; MU, mutant; NSCLC, non-small cell lung cancer; NSQ, non-squamous; SQ, squamous; TKI, tyrosine kinase inhibitor; WT, wild-type.



Interim Efficacy

ORR per Central Review by Cohort/Group



CI, confidence interval; *EGFR*, epidermal growth factor receptor; Int, intermediate; MU, mutant; NSQ, non-squamous; ORR, overall response rate; SQ, squamous; WT, wild-type.

- The NSQ *EGFR* WT NSCLC cohort met protocol-specified criteria for expansion in Stage 2 at interim analysis 3. Updated data at the time of interim analysis 4 are shown
- The NSQ *EGFR* MU NSCLC cohort met protocol-specified criteria for futility at interim analysis 4. The SQ cohort met criteria for futility at the previous interim analysis; final data shown

DOR, duration of response; *EGFR*, epidermal growth factor receptor; MU, mutant; NSCLC, non-small cell lung cancer; NSQ, non-squamous; OE, overexpressing; ORR, overall response rate; SQ, squamous; Teliso-V, telisotuzumab vedotin; WT, wild-type.

DOR per Central Review by Cohort/Group

Cohort/Group	mDOR by ICR, No. of Events/No. of Responders, Months [95% CI]
NSQ <i>EGFR</i> WT	8/19, 6.9 [4.1, NR]
<i>c-Met</i> high	5/12, 6.9 [2.4, NR]
<i>c-Met</i> int	3/7, NR [4.1, NR]
NSQ <i>EGFR</i> MU	2/5, NR [3.0, NR]
<i>c-Met</i> high	2/5, NR [3.0, NR]
<i>c-Met</i> int	NA
SQ	2/3, 4.4 [3.0, NR]

CI, confidence interval; DOR, duration of response; *EGFR*, epidermal growth factor receptor; ICR, independent central review; int, intermediate; mDOR, median duration of response; MU, mutant; NA, not available; NR, not reached; NSQ, non-squamous; SQ, squamous; WT, wild-type.

Objective Response Rate per Central Review for Subgroups Defined by Prior Therapies: NSQ *EGFR* WT Cohort

Cohort/Group	Prior Platinum, n/N (%)	Prior Platinum and Immune Checkpoint Inhibitor, n/N (%)
NSQ <i>EGFR</i> WT	18/50 (36.0)	15/37 (40.5)
<i>c-Met</i> high	11/21 (52.4)	9/16 (56.3)
<i>c-Met</i> int	7/29 (24.1)	6/21 (28.6)


EGFR, epidermal growth factor receptor; int, intermediate; NSQ, non-squamous; WT, wild-type.

Molecular oncogene analyses in tumors of patients with available tissue are underway.

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Non-Squamous *EGFR* Wildtype Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial

Nicolas Girard¹, D. Ross Camidge², Jair Bar³, Hidehito Horinouchi⁴, Jonathan Goldman⁵, Nathalie Daaboul⁶, Chunling Liu⁷, Irfan Çiçin⁸, Nuran Katgi⁹, Alona Zer¹⁰, Tudor Ciuleanu¹¹, Niels Reinmuth¹², David Planchard¹³, Aaron Mansfield¹⁴, Shobhit Bajaj¹⁵, Nancy Zhang¹⁶, Shilpen Patel¹⁶, Summer Xia¹⁶, Christine Ratajczak¹⁶, Shun Lu¹⁷

Best Reductions in Target Lesions^a per ICR (n=152)




^aOnly patients who had measurable disease at baseline and who had at least 1 measurable post-baseline assessment were included in this analysis. ICR, independent central review; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease.

- DCR was 59.5% for c-Met high, 58.3% for c-Met intermediate, and 58.9% for c-Met OE total

Toxicity

TRAEs^a Occurring in >5% of Patients



TRAE, ^a n (%)	c-Met OE Total (N=172)
Any grade	140 (81.4)
Grade ≥3	49 (28.5)
Serious TRAE	21 (12.2)
Leading to Teliso-V discontinuation	39 (22.7)
Leading to death	2 (1.2)

^aPer investigator assessment.
OE, overexpressing; Teliso-V, telisotuzumab vedotin; TRAE, treatment-related adverse event.

^aPer investigator assessment. ^bPneumonitis events shown are those with a MedDRA preferred term of “pneumonitis” according to the investigative site reporting. TRAEs with a preferred term of “ILD” according to investigative site reporting were noted in 4 (2.3%) patients.
ILD, interstitial lung disease; MedDRA, Medical Dictionary for Regulatory Activities; TRAEs, treatment-related adverse events.



Interim Safety and Efficacy

Summary of Treatment-Emergent Adverse Events

TEAEs, n (%)	Total N=136	
	Any Grade	Grade ≥3
Any TEAE	131 (96)	65 (48)
Most common any-grade TEAEs (≥10%)		
<i>Peripheral sensory neuropathy</i>	34 (25)	6 (4)
<i>Nausea</i>	30 (22)	1 (1)
<i>Hypoalbuminemia</i>	28 (21)	1 (1)
<i>Peripheral edema</i>	25 (18)	0
<i>Blurred vision</i>	25 (18)	1 (1)
<i>Decreased appetite</i>	24 (18)	0
<i>Fatigue</i>	22 (16)	5 (4)
<i>Anemia</i>	19 (14)	3 (2)
<i>Dyspnea</i>	19 (14)	4 (3)
<i>Asthenia</i>	18 (13)	3 (2)
<i>Increased gamma-glutamyl transferase</i>	18 (13)	3 (2)
<i>Keratitis</i>	18 (13)	0
<i>Constipation</i>	16 (12)	1 (1)
<i>Cough</i>	14 (10)	0
<i>Diarrhea</i>	14 (10)	0
<i>Dizziness</i>	14 (10)	0
<i>Malignant neoplasm progression</i>	14 (10)	11 (8)
<i>Vomiting</i>	14 (10)	1 (1)


Any TEAE related to Teliso-V*	104 (76)
Any serious TEAE	41 (30)
Any TEAE leading to Teliso-V discontinuation	45 (33)
Any TEAE leading to Teliso-V discontinuation possibly related to Teliso-V*	18 (13)
Any TEAE leading to death possibly related to Teliso-V*	2 (1)

*Per investigator assessment.

TEAEs, treatment-emergent adverse events; Teliso-V, telisotuzumab vedotin.

- Treatment-emergent adverse events leading to death assessed by investigator as possibly related to Teliso-V were sudden death and pneumonitis, in 1 patient each. Both were in the squamous cohort
- Any-grade pneumonitis was reported in 9 patients (6.6%) and grade ≥3 pneumonitis was reported in 3 patients (2.2%)

TeliMET NSCLC-01 Study Design



Faculty Case Presentations

Case Presentation – Dr Sands: 52-year-old woman

- 52 yr old woman presented to PCP with dry cough that had persisted for 1 year.
- CXR showed right lower lobe mass
- CT chest: 5.3 x 4.4 cm right lower lobe mass with right hilar adenopathy.
- PET showed RLL mass, hilar, mediastinal, and supraclavicular adenopathy as well as T10 vertebral body lesion.
- MRI brain showed 2 brain mets, which were treated with SRS prior to starting systemic therapy
- Started treatment on Carboplatin, pemetrexed, and pembrolizumab

Pathology:

metastatic adenocarcinoma
TTF-1 +, p40 rare +
negative for GATA-3, ER, PR, HER2).
ALK and ROS1 IHC negative
PD-L1 20%
EGFR exon 19 del/L858R negative
from cfDNA.

Case Presentation – Dr Sands: 52-year-old woman (cont'd)

- About 8 months into systemic therapy, progression was noted in previously radiated brain mets. Treated with SRS again.
- About 9 months after starting systemic therapy, progression was noted in multiple sites throughout brain.
- Genomic testing showed RET fusion. Patient started LOXO-292 (selpercatinib).
- After >2 years on treatment, progression noted in multiple brain mets, underwent whole brain radiation.
- 6 months later, palliative radiation to C6 – T2.
- After >3 years LOXO-292, progression noted.

Case Presentation – Dr Sands: 52-year-old woman (cont'd)

- Genomics testing on sample from liver biopsy showed HER2 amplification, leading to IHC that was HER2 3+
 - Started Trastuzumab deruxtecan with concurrent selpercatinib
 - About 18 months of disease control was noted before progression seen on CT scans and evidence of leptomeningeal disease seen on MRI.
- Genomics:**
- Two copy deletion CDKN2A/B MTAP
 - RET gain (supports presence of RET fusion with breakpoint in intron 11)
 - ERBB2 amp (36 copies)
- HER2 IHC performed, 3+

Questions for the Faculty

In what line of therapy are you typically offering T-DXd for HER2-mutant NSCLC? What about HER2-overexpressing (IHC 3+) disease?

How often do you encounter patients like this one with HER2 mutations or HER2 overexpression and another actionable genomic alteration? How do you sequence T-DXd relative to other targeted therapies in those cases? How, if at all, does that vary based on the other biomarker that is present?

In your experience, how effective is T-DXd for patients with CNS metastases?

Questions for the Faculty

Are there scenarios in which you would recommend T-DXd in the first-line setting?

Are there scenarios in which you would recommend T-DXd for patients with HER2-amplified but not HER2-overexpressing NSCLC? What about HER2 IHC 1+ or 2+ disease?

Where do you see HER2-targeted tyrosine kinase inhibitors such as zongertinib fitting into the management of HER2-mutant NSCLC?

Case presentation

– Prof Garassino

A 64-year-old man, with a 40-pack-year smoking history, who quit five years ago, presents with chest pain and dyspnea.

Computed tomography (CT) and positron emission tomography (PET) scans reveal a right lower lobe mass, mediastinal and hilar adenopathy, and hepatic lesions concerning for metastases.

CT guided biopsy of one of the hepatic lesions reveals non-small-cell lung cancer (NSCLC), adenocarcinoma histology.

Magnetic resonance imaging (MRI) of the brain is negative for metastases.

The PD-L1 tumor proportion score (TPS) is 50%.

This patient's tumor is negative for EGFR mutations, ALK, ROS-1 or RET rearrangements, MET exon 14 skipping mutation, BRAF V600E mutation, or NTRK1/2/3 gene fusion. HER2 positive (IHC).

Patient started pembrolizumab single agent.

Case presentation

– Prof Garassino (cont'd)

The patient progressed after 12 months on pembrolizumab with an initial response.

Started Trastuzumab deruxtecan 5.4 mg/Kg.

After a month, the patient developed ILD and was treated with steroids with some benefit.

Unfortunately, the patient had a deterioration of his general condition and died.

Questions for the Faculty

How do you prevent and manage gastrointestinal toxicities with T-DXd?

How do you screen for interstitial lung disease (ILD) in patients receiving T-DXd? How do you manage Grade 1 ILD? What about Grade 2 ILD? Will you rechallenge with T-DXd after ILD symptoms have resolved in either case?

How do you factor in the presence of coexisting cardiopulmonary morbidities (COPD, CAD) when making decisions about T-DXd, and how problematic are nonspecific pulmonary densities on imaging?

Questions for the Faculty

When and how do you test for c-Met overexpression in patients with NSCLC? How is “high c-Met overexpression” defined for the purposes of using telisotuzumab vedotin (teliso-V)?

In what line of therapy are you typically offering teliso-V for high c-Met-overexpressing NSCLC?

Would you offer teliso-V to a patient with lower c-Met expression under any circumstances?

What are the most common adverse events associated with teliso-V, and how do you monitor for and manage them?

Agenda

Module 1: Role of Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Tumor Mutation — Prof Peters

Module 2: Targeted and Other Novel Therapeutic Strategies for Relapsed Metastatic NSCLC — Prof Garassino

Module 3: Potential Role of TROP2-Targeted Antibody-Drug Conjugates in Advanced NSCLC — Dr Sands

Module 4: Evolving Role of Immune Checkpoint Inhibitors in the Care of Patients with Nonmetastatic NSCLC — Dr Heymach

Potential Role for TROP2-Targeting ADCs In Advanced NSCLC

Jacob Sands, MD

May 2025

Trophoblast-Cell Surface Antigen 2 (TROP2)

- Initially discovered in human trophoblast and choriocarcinoma cells
- An intracellular calcium signal transducer overexpressed in various epithelial cancers
- Associated with poor prognosis in some data sets
- Not expressed in normal tissue
- Encoded by TACSTD2
- Role is not fully understood but thought to have a role in growth and proliferation of carcinoma cells
- Thought to be an oncogene with a role in initiating signaling mechanisms that can increase tumorigenicity, aggressiveness, and metastasis

Basu A, et al. *Int J Cancer*. 1995

Lipinski M, et al. *Proc Natl Acad Sci U S A*. 1981

Shvartsur A, et al. *Genes Cancer*. 2015

Wang J, et al. *Mol Cancer Ther*. 2008

Ohmachi, et al. *Clin Cancer Res*. 2006;12:3057

Trop2 Antibody-Drug Conjugates


	Datopotamab Deruxtecan	Sacituzumab Govitecan	Sacituzumab Tirumotecan
Antibody	Trop2	*Trop2	*Trop2
Linker	Hydrolyzable	Hydrolyzable	Hydrolyzable
Payload	+Exetecan derivative	+SN-38	+Belotecan derivative
DAR	4:1	7.6:1	7.4:1

* Same antibody

+ All are topoisomerase I inhibitor payloads


Datopotamab deruxtecan (Dato-DXd)

- TROPION Lung-01



Datopotamab deruxtecan (Dato-DXd)

- In the setting of Actionable Genomic Alteration:
 - 15.6 vs 9.8 months (HR [95% CI], 0.65 [0.40–1.08]);



Datopotamab deruxtecan (Dato-DXd)


- TROPION Lung-01 and TROPION Lung-05 Combined Cohort

TROPION-Lung05 (Phase II study)

- **Presence of ≥ 1 actionable genomic alteration** (*EGFR*, *ALK*, *ROS1*, *NTRK*, *BRAF*, *MET* exon 14 skipping, or *RET*)
 - ≥ 1 line of targeted therapy
 - 1–2 prior cytotoxic agent-containing therapies including Pt-CT in the metastatic setting
 - Radiographic disease progression after most recent therapy

TROPION-Lung01 (Phase III study)

- **In those with actionable genomic alterations** (*EGFR*, *ALK*, *ROS1*, *NTRK*, *BRAF*, *MET* exon 14 skipping, or *RET*)
 - 1–2 prior approved targeted therapies + Pt-CT, and ≤ 1 anti-PD-(L)1 mAb
 - No prior docetaxel




Endpoints:

- ORR per BICR
- BOR per BICR
- DCR per BICR
- DOR per BICR
- PFS per BICR
- OS
- Safety

Datopotamab deruxtecan (Dato-DXd)

- TROPION Lung-01 and TROPION Lung-05 Combined Cohort


Characteristic, n (%)	EGFRm Pool (N=117)	TROPION-Lung05 (N=78)	TROPION-Lung01 (N=39)
Median age (range), years	63 (36–81)	63 (36–77)	62 (39–81)
Sex, female	73 (62.4)	52 (66.7)	21 (53.8)
Race			
Asian	81 (69.2)	55 (70.5)	26 (66.7)
White	27 (23.1)	20 (25.6)	7 (17.9)
Black or African American	1 (0.9)	0	1 (2.6)
Other/missing	8 (6.8)	3 (3.8)	5 (12.8)
ECOG PS			
0	39 (33.3)	24 (30.8)	15 (38.5)
1	78 (66.7)	54 (69.2)	24 (61.5)
Smoker ^a	55 (47.0)	34 (43.6)	21 (53.8)
Nonsquamous histology ^b	115 (98.3)	77 (98.7)	38 (97.4)
Brain metastasis at study entry	36 (30.8)	21 (26.9)	15 (38.5)
Median lines systemic therapy (range) ^c	3 (1–5)	3 (1–5)	2 (1–5)
Prior osimertinib ^d			
First line	96 (82.1)	61 (78.2)	35 (89.7)
Second line	47 (40.2)	27 (34.6)	20 (51.3)
Second line	34 (29.1)	20 (25.6)	14 (35.9)



Datopotamab deruxtecan (Dato-DXd)

Response	<i>EGFR</i> m Pool (N=117)	Prior Osimertinib (N=96)
Confirmed ORR,^a n (%) [95% CI]	50 (42.7) [33.6–52.2]	43 (44.8) [34.6–55.3]
BOR, n (%)		
CR	5 (4.3)	4 (4.2)
PR	45 (38.5)	39 (40.6)
SD	48 (41.0)	37 (38.5)
Non-CR/Non-PD	3 (2.6)	2 (2.1)
PD	12 (10.3)	10 (10.4)
NE	4 (3.4)	4 (4.2)
Median DOR, months (95% CI)	7.0 (4.2–9.8)	6.9 (4.2–9.8)
DCR,^b n (%) [95% CI]	101 (86.3) [78.7–92.0]	82 (85.4) [76.7–91.8]
Median PFS, months (95% CI)	5.8 (5.4–8.2)	5.7 (5.4–7.9)
Median OS, months (95% CI)	15.6 (13.1–19.0)	14.7 (13.0–18.3)


Ahn et al. ESMO Asia 2024



Datopotamab deruxtecan (Dato-DXd)

	<i>EGFRm</i> Pool (N=117)
TRAEs, n (%)	111 (95)
Grade ≥ 3	27 (23)
Associated with dose reduction	26 (22)
Associated with dose delay	27 (23)
Associated with treatment discontinuation	6 (5)
Associated with death	0 (0)
Serious TRAEs	9 (8)
AESIs, n (%)	
Stomatitis/oral mucositis^a	81 (69)
Grade 3 ^b	11 (9)
Ocular surface events^a	38 (32)
Grade 3 ^b	3 (3)
Adjudicated drug-related ILD	5 (4)
Grade 3 ^b	1 (1)

^bNo grade 4 or 5 events occurred



Ahn et al. ESMO Asia 2024


Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated NSCLC

Press Release: January 13, 2025


The Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Review in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) who have received prior systemic therapies, including an EGFR-directed therapy.

In a pooled analysis of patients with previously treated advanced or metastatic EGFRm NSCLC in the TROPION-Lung05 and TROPION-Lung01 trials presented at the European Society for Medical Oncology (ESMO) Asia 2024 Congress, datopotamab deruxtecan demonstrated a confirmed objective response rate (ORR) of 42.7% (95% confidence interval [CI] 33.6-52.2) as assessed by blinded independent central review (BICR) and a median duration of response (DoR) of 7.0 months (95% CI 4.2-9.8). The safety profile of datopotamab deruxtecan was consistent with previous reports from the TROPION-Lung05 and TROPION-Lung01 trials, with no new safety concerns identified.

Sacituzumab govitecan




Sacituzumab govitecan



	Sacituzumab govitecan	Docetaxel
ORR	13.7%	18.1%
mDOR	6.7 mos	5.8 mos
mPFS	4.1 mos	3.9 mos
mOS	11.1 mos	9.8 mos

Sacituzumab govitecan

- Sub-group of those without response to prior line of immunotherapy (may also include chemo).





Event	SG (n = 296), No. (%)		Docetaxel (n = 288), No. (%)	
	Any Grade	Grade ≥3	Any Grade	Grade ≥3
TEAEs ^{a,b}	295 (99.7)	197 (66.6)	282 (97.9)	218 (75.7)
TEAEs reported in ≥10% in either group ^c				
Fatigue	168 (56.8)	37 (12.5)	161 (55.9)	28 (9.7)
Diarrhea	156 (52.7)	31 (10.5)	97 (33.7)	11 (3.8)
Alopecia	128 (43.2)	2 (0.7)	86 (29.9)	2 (0.7)
Nausea	123 (41.6)	5 (1.7)	75 (26.0)	3 (1.0)
Anemia	119 (40.2)	19 (6.4)	89 (30.9)	17 (5.9)
Neutropenia	111 (37.5)	73 (24.7)	123 (42.7)	106 (36.8)
Constipation	86 (29.1)	0	49 (17.0)	1 (0.3)
Decreased appetite	78 (26.4)	7 (2.4)	69 (24.0)	6 (2.1)
Vomiting	62 (20.9)	7 (2.4)	43 (14.9)	6 (2.1)
Cough	46 (15.5)	0	45 (15.6)	1 (0.3)
Dyspnea	42 (14.2)	4 (1.4)	51 (17.7)	13 (4.5)
Stomatitis	39 (13.2)	3 (1.0)	58 (20.1)	7 (2.4)
Leukopenia	38 (12.8)	15 (5.1)	63 (21.9)	50 (17.4)
Pruritus	37 (12.5)	1 (0.3)	11 (3.8)	0
Pyrexia	37 (12.5)	2 (0.7)	34 (11.8)	2 (0.7)
Back pain	33 (11.1)	2 (0.7)	19 (6.6)	2 (0.7)
Abdominal pain	31 (10.5)	3 (1.0)	14 (4.9)	0
Arthralgia	30 (10.1)	2 (0.7)	29 (10.1)	1 (0.3)
Rash	30 (10.1)	0	19 (6.6)	0
Febrile neutropenia	23 (7.8)	23 (7.8)	29 (10.1)	27 (9.4)
Lymphopenia	23 (7.8)	9 (3.0)	31 (10.8)	12 (4.2)
Peripheral edema	16 (5.4)	0	35 (12.2)	4 (1.4)
Dysgeusia	14 (4.7)	0	30 (10.4)	0
Peripheral neuropathy	11 (3.7)	0	38 (13.2)	2 (0.7)
Treatment-related ^c	279 (94.3)	156 (52.7)	262 (91.0)	173 (60.1)

Event	SG (n = 296), No. (%)		Docetaxel (n = 288), No. (%)	
	Any Grade	Grade ≥3	Any Grade	Grade ≥3
TEAEs ^{a,b}	295 (99.7)	197 (66.6)	282 (97.9)	218 (75.7)
TEAEs reported in ≥10% in either group ^c				
Fatigue	168 (56.8)	37 (12.5)	161 (55.9)	28 (9.7)
Diarrhea	156 (52.7)	31 (10.5)	97 (33.7)	11 (3.8)
Alopecia	128 (43.2)	2 (0.7)	86 (29.9)	2 (0.7)
Nausea	123 (41.6)	5 (1.7)	75 (26.0)	3 (1.0)
Anemia	119 (40.2)	19 (6.4)	89 (30.9)	17 (5.9)
Neutropenia	111 (37.5)	73 (24.7)	123 (42.7)	106 (36.8)
Constipation	86 (29.1)	0	49 (17.0)	1 (0.3)
Decreased appetite	78 (26.4)	7 (2.4)	69 (24.0)	6 (2.1)
Vomiting	62 (20.9)	7 (2.4)	43 (14.9)	6 (2.1)
Cough	46 (15.5)	0	45 (15.6)	1 (0.3)
Dyspnea	42 (14.2)	4 (1.4)	51 (17.7)	13 (4.5)
Stomatitis	39 (13.2)	3 (1.0)	58 (20.1)	7 (2.4)
Leukopenia	38 (12.8)	15 (5.1)	63 (21.9)	50 (17.4)
Pruritus	37 (12.5)	1 (0.3)	11 (3.8)	0
Dysrexia	27 (9.1)	2 (0.7)	24 (8.3)	2 (0.7)
TEAEs leading to discontinuation	29 (9.8)		48 (16.7)	
Treatment-related ^c	20 (6.8)		41 (14.2)	
TEAEs leading to death	10 (3.4)		13 (4.5)	
Treatment-related ^d	4 (1.4)		3 (1.0)	
TEAEs leading to dose reduction	87 (29.4)		112 (38.9)	
TEAEs leading to treatment interruption	171 (57.8)		81 (28.1)	
Peripheral neuropathy	11 (3.7)	0	38 (13.2)	2 (0.7)
Treatment-related ^e	279 (94.3)	156 (52.7)	262 (91.0)	173 (60.1)

Sacituzumab tirumotecan (Sac-TMT)

	KL264-01 cohort 3A			SKB264-II-08 cohort 1	SKB264-II-08 cohort 2
	Overall (n=43)	EGFR-WT (n=21)	EGFR-mutant (n=22)	Overall (n=32)	Overall (n=32)
EGFR primary mutation, n (%)^a					
Exon 19 deletion	-	-	10 (45)	20 (63)	17 (53)
Exon 21 L858R	-	-	8 (36)	10 (31)	15 (47)
Others ^b	-	-	2 (9)	2 (6)	0
Unknown	-	-	2 (9)	0	0
Previous lines of therapy, n (%)					
Median (range)	2 (1-10)	2 (1-10)	2 (1-7)	3 (1-5)	1 (1-2)
1	13 (30)	7 (33)	6 (27)	3 (9)	23 (72)
2	14 (33)	7 (33)	7 (32)	11 (34)	9 (28)
≥3	16 (37)	7 (33)	9 (41)	18 (56)	0
Previous systemic therapy, n (%)					
Platinum-based chemotherapy	33 (77)	21 (100)	12 (55)	32 (100)	0
Immunotherapy	23 (53)	21 (100)	2 (9)	0	0
3rd generation EGFR TKI	14 (33)	0	14 (64)	28 (88)	28 (88)

Sacituzumab tirumotecan (Sac-TMT)



n (%)	KL264-01 cohort 3A (n=43)		SKB264-II-08 cohort 1 (n=32)		SKB264-II-08 cohort 2 (n=32)		Combined (n=107)	
	Any-grade	Grade ≥3	Any-grade	Grade ≥3	Any-grade	Grade ≥3	Any-grade	Grade ≥3
Anemia	31 (72)	13 (30)	29 (91)	8 (25)	30 (94)	4 (13)	90 (84)	25 (23)
White blood cell count decreased	24 (56)	11 (26)	23 (72)	5 (16)	29 (91)	7 (22)	76 (71)	23 (21)
Neutrophil count decreased	23 (53)	15 (35)	22 (69)	12 (38)	26 (81)	15 (47)	71 (66)	42 (39)
Stomatitis	22 (51)	4 (9)	23 (72)	8 (25)	20 (63)	3 (9)	65 (61)	15 (14)
Alopecia	23 (53)	0	10 (31)	0	18 (56)	0	51 (48)	0
Nausea	16 (37)	0	12 (38)	0	12 (38)	0	40 (37)	0
Decreased appetite	16 (37)	0	10 (31)	0	10 (31)	0	36 (34)	0
Platelet count decreased	10 (23)	1 (2)	15 (47)	3 (9)	10 (31)	2 (6)	35 (33)	6 (6)
Rash	17 (40)	2 (5)	3 (9)	0	12 (38)	0	32 (30)	2 (2)
Vomiting	15 (35)	2 (5)	9 (28)	1 (3)	7 (22)	0	31 (29)	3 (3)
Weight decreased	6 (14)	1 (2)	15 (47)	0	10 (31)	0	31 (29)	1 (1)
Weakness	3 (7)	1 (2)	11 (34)	1 (3)	11 (34)	1 (3)	25 (23)	3 (3)
Hypoalbuminemia	10 (23)	0	4 (13)	0	4 (13)	0	18 (17)	0
ALT increased	8 (19)	0	4 (13)	0	5 (16)	0	17 (16)	0
AST increased	6 (14)	0	4 (13)	0	6 (19)	0	16 (15)	0
Pruritus	9 (21)	0	2 (6)	0	2 (6)	0	13 (12)	0
Lymphocyte count decreased	8 (19)	2 (5)	2 (6)	0	2 (6)	1 (3)	12 (11)	3 (3)
Hyperglycemia	4 (9)	0	4 (13)	0	3 (9)	0	11 (10)	0
Skin hyperpigmentation	8 (19)	0	0	0	0	0	8 (7)	0
Dizziness	3 (7)	0	4 (13)	0	1 (3)	0	8 (7)	0
Mouth ulceration	5 (12)	0	1 (3)	0	0	0	6 (6)	0
Proteinuria	2 (5)	0	4 (13)	0	1 (3)	0	7 (7)	0
Fatigue	5 (12)	0	0	0	0	0	5 (5)	0

Will a biomarker open treatment population?

- Biomarker developed from Tropion-Lung 01 study

(Datopotamab deruxtecan)

4

Patient Biomarker Status Determination



≥75% of tumor cells with
TROP2 NMR ≤0.56



<75% of tumor cells with
TROP2 NMR ≤0.56

Calculates TROP2 NMR for
every tumor cell

Membrane OD

Membrane OD + Cytoplasm OD

Lower NMR → higher cytoplasm proportion

Prevalence

Histology subgroup	Prevalence of TROP2 QCS-NMR+, % (n)
BEP, n=352	
NSQ	66% (179/272)
NSQ/non-AGA	63% (140/221)
NSQ/AGA	76% (39/51)
SQ	44% (35/80)

TROPION-Lung02: Dato-DXd + Pembrolizumab ± Chemo

- TROPION-Lung02 is the first study evaluating Dato-DXd + pembrolizumab ± platinum CT^a in advanced NSCLC without actionable genomic alterations^b (NCT04526691)
 - The safety of the Dato-DXd + pembrolizumab doublet was established prior to evaluation of the platinum-containing triplet
 - The safety of Dato-DXd 4-mg/kg combinations was established prior to evaluation of 6-mg/kg combinations

Key eligibility criteria


- Advanced/metastatic NSCLC**
- Dose escalation^c:** ≤2 lines of prior therapy^d
- Dose expansion**
 - ≤1 line of platinum-based CT (cohorts 1 and 2)^d
 - Treatment naive (cohort 2; enrollment after Jun 30, 2022)^d
 - Treatment naive (cohorts 3-6)^d

	Dato-DXd IV Q3W	+	pembro IV Q3W	+	platinum CT IV Q3W	
Cohort 1 (n=20):	4 mg/kg	+	200 mg			Doublet
Cohort 2 (n=44):	6 mg/kg	+	200 mg			
Cohort 3 (n=20):	4 mg/kg	+	200 mg	+	carboplatin AUC 5	Triplet
Cohort 4 (n=30):	6 mg/kg	+	200 mg	+	carboplatin AUC 5	
Cohort 5 (n=12):	4 mg/kg	+	200 mg	+	cisplatin 75 mg/m ²	
Cohort 6 (n=10):	6 mg/kg	+	200 mg	+	cisplatin 75 mg/m ²	


- Primary objectives:** safety and tolerability
- Secondary objectives:** efficacy, pharmacokinetics, and antidrug antibodies

TROPION-Lung02: Dato-DXd + Pembrolizumab $\pm$ Chemo

All patients (n=124)^a



Patients in the 1L setting (n=84)^a



TROPION-Lung02: Dato-DXd + Pembrolizumab $\pm$ Chemo

	All patients		Patients in 1L	
Response ^a	Doublet (n=61) ^b	Triplet (n=71) ^b	Doublet (n=34) ^b	Triplet (n=53) ^b
Confirmed + pending ORR, n (%)^{c,d} [95% CI]	23 (38) [26-51]	35 (49) [37-61]	17 (50) [32-68]	30 (57) [42-70]
Confirmed + pending BOR, n (%)^{d,e}				
Confirmed CR	0	1 (1)	0	1 (2)
Pending CR ^d	0	0	0	0
Confirmed PR	21 (34)	34 (48)	15 (44)	29 (55)
Pending PR ^d	2 (3)	0	2 (6)	0
SD, n (%) ^f	30 (49)	27 (38)	16 (47)	18 (34)
DCR, n (%) ^g	51 (84)	62 (87)	31 (91)	48 (91)
Median DOR, months [95% CI]	NE [8.8-NE]	NE [5.8-NE]	NE [5.5-NE]	NE [5.7-NE]

Preliminary PFS in all patients, median (95% CI), months: doublet, 8.3 (6.8-11.8); triplet 7.8 (5.6-11.1)^h

- In the 1L setting, the ORR (confirmed and pending)^d was 50% in patients receiving doublet therapy and 57% in those receiving triplet therapy
- Among all patients, the DCR was 84% (doublet) and 87% (triplet); in the 1L setting, the DCR was 91% in both therapy subgroups

TROPION-Lung02: Datopotamab Deruxtecan (Dato-DXd) plus Pembrolizumab (Pembro) with or without Platinum Chemotherapy (Pt-CT) as First-Line (1L) Therapy for Advanced Non-Small Cell Lung Cancer (aNSCLC)

Levy B et al.

ASCO 2025;Abstract 8501.

June 1, 2025

Arie Crown Theater | 8:12 AM CT

Ongoing Trials

- AVANZAR: 1L Non-sq NSCLC: Durva, Dato-DXd, Carbo
- TROPION Lung-07: 1L Non-sq PD-L1 <50%: Dato-DXd+pembro+/-chemo
- TROPION Lung-08: 1L Non-sq PD-L1 $\geq$ 50%: Pembro +/- Dato-DXd
- TROPION Lung-15: 2L EGFR: Dato-DXd +/- osi vs chemo
- EVOKE-03: 1L NSCLC, PD-L1 $\geq$ 50%: Pembro +/- Sacituzumab govitecan
- 1L Squam NSCLC: Carbo paclitaxel pembro → pembro +/- SacTMT
- 2L EGFR: SacTMT vs chemo (post osi progression)
- Trofuse-007: 1L NSCLC, PD-L1 $\geq$ 50%: Pembro +/- SacTMT

Faculty Case Presentations

Case Presentation – Prof Peters: 50-year-old male, never smoker


50 years old, never smoker

Mucinous adenocarcinoma of the right lower lobe, cT4 (>7 cm, ipsilateral lung lesions), cN2 (station 7), cM1a (contralateral lung lesions), stage IVA (8th TNM)

IHC: ALK or ROS1 negative, PD-L1 <1%

NGS-52 panel: no EGFR, BRAF or HER2 mutation

Detected mutations: KRAS (G12D, exon 2), GNAS (R201S, exon 8), RET (V648I, exon 11), FLT3 (S446L, exon 11)




Case Presentation – Prof Peters: 50-year-old male, never smoker (cont'd)

May 2021

First line - carboplatin-pemetrexed-pembrolizumab according to KEYNOTE-189


Treatment stopped in May 2023



Case Presentation – Prof Peters: 50-year-old male, never smoker (cont'd)

July 2023


Lung progression



Case Presentation – Prof Peters: 50-year-old male, never smoker (cont'd)

Second line - ipilimumab, nivolumab, carboplatin, and paclitaxel according to CheckMate 9LA

Best response: PD on November 2023




Case Presentation – Prof Peters: 50-year-old male, never smoker (cont'd)

November 2023

Third line: gemcitabine, vinorelbine, ipilimumab and nivolumab


Best response: PR



Case Presentation – Prof Peters: 50-year-old male, never smoker (cont'd)

July 2024

Pulmonary and LN progression





Case Presentation – Prof Peters: 50-year-old male, never smoker (cont'd)

August 2024

Fourth-line - gemcitabine and weekly docetaxel

Best response: hepatic PD, persistent thoracic partial response





Case Presentation – Prof Peters: 50-year-old male, never smoker (cont'd)

October 2024

Fifth-line with **datopotamab deruxtecan**

Hepatic complete response and persistent thoracic partial response

Toxicity: oral mucositis Grade 1-2





Case Presentation – Prof Peters: 50-year-old male, never smoker (cont'd)

Seven months after initiation of datopotamab deruxtecan

Hepatic & LN complete response and persistent pulmonary partial response

Toxicity: oral mucositis grade 1



Questions for the Faculty

If Dato-DXd were to become available for progressive EGFR-mutant NSCLC, in which line of treatment would you most likely use it, and how would this vary depending on the first-line therapy the patient had received (osimertinib monotherapy versus osimertinib/chemotherapy versus amivantamab/lazertinib)?

Questions for the Faculty

If Dato-DXd were to become available for NSCLC, would you consider it for a patient without a targetable tumor mutation who had exhausted other options? What about for a patient with a genomic alteration beyond EGFR?

How enthusiastic are you about the ongoing studies evaluating Dato-DXd in combination with immune checkpoint inhibition as initial therapy for metastatic NSCLC? Do you think these strategies will eventually reach the clinic?

Do you think we'll eventually be using the TROP2 QCS-NMR to select patients with NSCLC to receive Dato-DXd?

Questions for the Faculty

What preemptive strategies, if any, do you employ to prevent the development of oral mucositis/stomatitis associated with Dato-DXd? How do you manage oral mucositis/stomatitis when it occurs?

What is your approach to screening for ILD in patients with NSCLC receiving Dato-DXd? Does your approach to monitoring for and managing ILD associated with Dato-DXd differ in any way from ILD associated with T-DXd? If so, how?

What specific ocular adverse events have you encountered with Dato-DXd? How do you monitor for, mitigate and manage them?

Agenda

Module 1: Role of Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Tumor Mutation — Prof Peters

Module 2: Targeted and Other Novel Therapeutic Strategies for Relapsed Metastatic NSCLC — Prof Garassino

Module 3: Potential Role of TROP2-Targeted Antibody-Drug Conjugates in Advanced NSCLC — Dr Sands

Module 4: Evolving Role of Immune Checkpoint Inhibitors in the Care of Patients with Nonmetastatic NSCLC — Dr Heymach



The Evolving Role of Immune Checkpoint Inhibitors in the Care of Patients with Non-Metastatic NSCLC

John Heymach, M.D., Ph.D.

Chair, Dept. of Thoracic/Head and Neck
Medical Oncology
Ruth Legett Jones Distinguished Chair

Research To Practice
May 30, 2025

THE UNIVERSITY OF TEXAS

MD Anderson
Cancer Center

Making Cancer History®

Multiple Large Randomized Trials Support Substantial Clinical Benefit of Immune Checkpoint Inhibitors in Resectable NSCLC

Adjuvant ^a (N=2182)				Perioperative (N=1998)				Neoadjuvant (N=358)				
Study	KEYNOTE-091 ¹ N=1177		IMpower010 ² N=1005		KEYNOTE-671 ³ N=797		AEGEAN N=740		CheckMate 77T ⁴ N=461		CheckMate 816 ⁵ N=358	
Regimen	Pembro	Placebo	Atezo	BSC	Pembro + Chemo →Pembro	Placebo + Chemo →Placebo	Durva + Chemo →Durva	Placebo + Chemo →Placebo	Nivo + Chemo →Nivo	Placebo + Chemo →Placebo	Nivo + Chemo	Chemo
Median EFS/DFS (95% CI), mo	53.9 (46.2-67.0)	43.0 (35.0-51.6)	65.6 (NA, NA)	47.8 (NA, NA)	47.2 (32.9, NR)	18.3 (14.8, 22.1)	NR (42.3, NR)	30.0 (20.6, NR)	NR (28.9, NR)	18.4 (13.6, 28.1)	43.8 (30.6, NR)	18.4 (14.0, 26.7)
EFS/DFS HR (95% CI)	0.81 (0.68, 0.96)		0.85 (0.71, 1.01)		0.59 (0.48, 0.72)		0.69 (0.55, 0.88)		0.58 (0.42, 0.81)		0.66 (0.49, 0.90)	
Maturity	48%		50%		53%		39%		40%		52% (planned) ⁶	
Median follow-up	51.7 months		65.0 months		36.6 months		25.9 months		25.4 months		57.6 months	


Note: Most recent data from all studies (regardless of PD-L1).

^a For Adjuvant studies, randomization is after surgery and +/- adjuvant chemotherapy.

Atezo=atezolizumab; BSC=best supportive care; DFS=disease-free survival; Durva=durvalumab; EFS=event free survival; Nivo=nivolumab; NR=not reached/not estimable; NA=not available; Pembro=pembrolizumab.


1. Besse B, et al. ESMO-IO 2023. Abstract 120MO; 2. Wakelee HA, et al. ASCO 2024. Poster 297; 3. Spicer JD, et al. ESMO 2023. Abstract LBA56; 4. Cascone T, et al. ESMO 2023. Abstract LBA1; 5. Spicer JD, et al. ASCO 2024 [oral]. Abstract LBA8010; 6. Forde PM, et al. *N Engl J Med.* 2022;386(21):1973-1985.

Randomized studies of adjuvant ICB for resectable NSCLC



Impower-010 randomized study of adjuvant atezolizumab vs BSC: Primary endpoint of DFS (PDL1>1%, stage II-IIIa)


HR 0.66 (p=.0039) in PDL1> 1%
13.6% improvement in 2Y DFS



Keynote-91/PEARLS RP3 study of adjuvant pembrolizumab vs BSC for resectable NSCLC

Stage IB-IIIA
HR=0.76 (P=.0014,
95% CI 0.63-0.91)

A




Number at risk
(number censored)

Pembrolizumab	590	493	434	358	264	185	82	70	28	16	1	0
	(0)	(30)	(36)	(84)	(150)	(216)	(306)	(313)	(352)	(363)	(377)	(378)
Placebo	587	493	409	326	241	160	72	57	22	18	1	0
	(0)	(5)	(13)	(56)	(118)	(183)	(259)	(273)	(305)	(309)	(326)	(327)


PD-L1>50%
HR=0.82 (P=.14,
95% CI , 0.57-1.18)

B




	168	145	126	99	69	50	26	22	7	4	0	0
	(0)	(8)	(9)	(24)	(49)	(66)	(90)	(93)	(107)	(110)	(114)	(114)
	165	140	121	100	75	54	28	22	8	6	1	0
	(0)	(0)	(2)	(16)	(37)	(53)	(76)	(81)	(94)	(96)	(101)	(102)

Randomized studies of neoadjuvant or perioperative (neoadjuvant+adjuvant) ICB for resectable NSCLC



Checkmate 816 study: addition of neoadjuvant nivolumab to CT improves EFS in resectable stage IB-IIIA NSCLC




No. at Risk

Nivolumab plus chemotherapy	179	151	136	124	118	107	102	87	74	41	34	13	6	3	0
Chemotherapy alone	179	144	126	109	94	83	75	61	52	26	24	13	11	4	0

77T study of perioperative nivolumab in resectable NSCLC


77T achieved primary endpoint of EFS (HR 0.58) with 20% improvement in 18m EFS



No. at Risk

Nivolumab	229	208	173	157	141	134	115	89	69	46	20	7	4	2	0
Chemotherapy	232	204	165	138	118	106	78	59	44	29	19	10	6	1	0

KN 671 of perioperative pembrolizumab: primary endpoint of EFS




No. at Risk

Pembrolizumab group	397	330	236	172	117	72	42	11	0	0
Placebo group	400	294	183	124	74	38	24	9	1	0

B Subgroup Analysis of Event-free Survival


Subgroup	Pembrolizumab Group no. of events/no. of participants	Placebo Group no. of events/no. of participants	Hazard Ratio for Event or Death (95% CI)
All patients	139/397	205/400	0.58 (0.46–0.72)
Age			
<65 yr	74/221	113/214	0.53 (0.39–0.71)
≥65 yr	65/176	92/186	0.64 (0.46–0.88)
Sex			
Female	31/118	55/116	0.44 (0.28–0.68)
Male	108/279	150/284	0.63 (0.49–0.80)
Race			
White	85/250	123/239	0.54 (0.41–0.72)
Other	46/134	70/145	0.62 (0.42–0.89)
Geographic region			
East Asia	43/123	57/121	0.66 (0.45–0.99)
Other	96/274	148/279	0.54 (0.41–0.69)
Smoking status			
Current smoker	37/96	57/103	0.52 (0.34–0.78)
Former smoker	84/247	128/250	0.57 (0.43–0.75)
Never smoked	18/54	20/47	0.68 (0.36–1.30)
Pathological stage			
II	34/118	48/121	0.65 (0.42–1.01)
III	105/279	157/279	0.54 (0.42–0.70)
Histologic features			
Nonsquamous	73/226	107/227	0.58 (0.43–0.78)
Squamous	66/171	98/173	0.57 (0.41–0.77)
PD-L1 TPS (50% cutoff)			
<50%	107/265	142/266	0.64 (0.49–0.82)
≥50%	32/132	63/134	0.42 (0.28–0.65)
PD-L1 TPS (1% cutoff)			
<1%	63/138	80/151	0.77 (0.55–1.07)
≥1%	76/259	125/249	0.47 (0.36–0.63)
PD-L1 TPS			
<1%	63/138	80/151	0.77 (0.55–1.07)
1–49%	44/127	62/115	0.51 (0.34–0.75)
≥50%	32/132	63/134	0.42 (0.28–0.65)
EGFR mutation			
No	31/111	64/127	0.48 (0.31–0.74)
Yes	1/14	10/19	0.09 (0.01–0.74)
Unknown	107/272	131/254	0.64 (0.49–0.83)
ALK translocation			
No	29/104	76/133	0.41 (0.26–0.62)
Unknown	106/281	128/258	0.63 (0.49–0.82)



AEGEAN EFS primary endpoint (BICR in mITT)

First planned interim analysis of EFS

A Event-free Survival



AEGEAN regimen achieved primary endpoint of EFS (HR 0.68) with 11% improvement in 2Y EFS

	No. of Events/ No. of Patients	Median Event-free Survival (95%CI) mo
Durvalumab	98/366 (26.8)	NR (31.9–NR)
Placebo	138/374 (36.9)	25.9 (18.9–NR)


Stratified hazard ratio for disease progression, recurrence, or death, 0.68 (95% CI, 0.53–0.88)
P=0.004 by stratified log-rank test

No. at Risk


Durvalumab	366	336	271	194	140	90	78	50	49	31	30	14	11	3	1	1	0
Placebo	374	339	257	184	136	82	74	53	50	30	25	16	13	1	1	0	0

Neoadjuvant, adjuvant, or both? Preclinical and Clinical Studies Support the Superiority of Neoadjuvant or Perioperative ICI vs Adjuvant ICI

NSCLC Model




SWOG S1801 (Melanoma)



Perioperative pembro appears more effective than adjuvant pembro


KEYNOTE-091 (Adjuvant Treatment)

HR: 0.76 (95% CI: 0.63, 0.91)




KEYNOTE-671 (Perioperative Treatment)

HR: 0.58 (95% CI: 0.46, 0.72)



No. at risk										
Pembrolizumab group	397	330	236	172	117	72	42	11	0	0
Placebo group	400	294	183	124	74	38	24	9	1	0


Comparison of neoadjuvant CM816 vs perioperative CM-77T: landmark EFS from definitive surgery



- HR (95% CI): ATT^d weighted analysis, 0.56 (0.35–0.90); unweighted analysis, 0.59 (0.38–0.92)

Can we select adjuvant therapy based on path CR status? KN 671 suggests benefit for adjuvant in both path CR and non-path CR groups

B Event-free Survival According to Pathological Complete Response



pCR group: HR 0.33

If the pCR group is benefitting so much, shouldn't they continue? (still >20% chance of recurrence)

Non-pCR group: HR 0.69


If the no pCR group hasn't responded as well, should they get a different type of, or intensified, therapy?

No. at Risk

With pathological complete response										
Pembrolizumab group	72	72	59	46	33	15	8	1	0	0
Placebo group	16	14	12	10	9	5	4	0	0	0
Without pathological complete response										
Pembrolizumab group	325	258	177	126	84	57	34	10	0	0
Placebo group	384	280	171	114	65	33	20	9	1	0


Mechanism of action of monalizumab and oleclumab

Monalizumab blocks the inhibitory interaction between NKG2A and HLA-E, activating NK cells and CD8+ T cells




Thorbald van Hall et al. J Immunother Cancer 2019;7:263

Oleclumab blocks CD73, an enzyme involved in the generation of immunosuppressive adenosine




Augustin et al, JITC 2022; 10:e004089

NeoCOAST-2: Open-label, multi-arm platform study in perioperative NSCLC




Path CR rates in different durva+chemo combination arms (note: durva+chemo had path CR 17% in Aegean)



Five year outcomes from PACIFIC: durvalumab after chemoRT for unresectable stage III NSCLC


PFS HR 0.55, 14% improvement in 5Y PFS



No. at risk:

Time (months)	0	3	6	9	12	15	18	21	24	27	30	33	36	39	42	45	48	51	54	57	60	63	66	69	72
Durvalumab	476	377	301	267	215	190	165	147	137	128	119	110	103	97	92	85	81	78	67	57	34	22	11	5	1
Placebo	237	164	105	87	68	56	48	41	37	36	30	27	26	25	24	24	22	21	19	19	14	6	4	1	1

OS HR 0.72, 10% improvement in 5Y OS




No. at risk:

Time (months)	0	3	6	9	12	15	18	21	24	27	30	33	36	39	42	45	48	51	54	57	60	63	66	69	72	75
Durvalumab	476	464	431	414	385	364	343	319	298	289	273	264	252	241	236	227	218	207	196	183	134	91	40	18	2	0
Placebo	237	220	199	179	171	156	143	133	123	116	107	99	97	93	91	83	78	77	74	72	56	33	16	7	2	0

Spigel et al, JCO 40:12, 2022

Coast: a randomized phase II study of consolidation durvalumab combinations in unresectable stage III NSCLC


Treatment Arm	No. of Events/ Total No. of Patients (%)	Median PFS, Months (95% CI) ^a	12-Month PFS Rate, % (95% CI)	HR, % (95% CI) ^{b,c}
Durvalumab + monalizumab	21/62 (33.9)	15.1 (13.6 to NE)	72.7 (58.8 to 82.6)	0.42 (0.24 to 0.72)
Durvalumab + oleclumab	22/60 (36.7)	NR (10.4 to NE)	62.6 (48.1 to 74.2)	0.44 (0.26 to 0.75)
Durvalumab	38/67 (56.7)	6.3 (3.7 to 11.2)	33.9 (21.2 to 47.1)	–




No. at risk:										
Durvalumab + monalizumab	62	55	46	44	41	35	25	11	6	1
Durvalumab + oleclumab	60	49	46	40	37	30	22	13	9	0
Durvalumab	67	50	32	27	20	16	13	9	7	0

Given the efficacy of perioperative regimens for N2 disease, can induction chemo-IO be used for borderline resectable cases? The MDT-BRIDGE study

Phase 2 for stage IIB to IIIB, N2+ NSCLC testing induction chemo+ durvalumab, followed by restaging, then assessment of operability with options of surgery→adjuvant durva (Aegean) or chemoRT then durvalumab (Pacific)



Evolving paradigm for non-metastatic, non-driver NSCLC






The evolving paradigm for non-metastatic NSCLC: where are we in 2025?

- Neoadjuvant, adjuvant, and perioperative IO regimens are all approved for resectable NSCLC
- We have 3 positive RCT of perioperative IO with similar designs that have generally yielded similar, clinically meaningful benefits
 - AEGEAN (durva), KN671 (pembro), and CM-77T (nivo)
- Multiple lines of evidence suggest that:
 - Neoadjuvant>adjuvant, neoadjuvant+adjuvant > neoadjuvant or adjuvant.
 - There is likely benefit to adjuvant IO after neoadjuvant IO, whether or not patients have had a path CR.
- Key questions for the field include how to intensify non-path CR groups, and how to treat borderline resectable disease

Faculty Case Presentations

Case Presentation – Prof Peters: 77-year-old female, former smoker

- 77-year-old female
- Former smoker (50py)
- September 2019: dysphonia
- H&N exam: left vocal cord paralysis, weight loss 10%
- PS 1
- CT scan and PET-CT (Sept 2019)



Case Presentation – Prof Peters: 77-year-old female, former smoker (cont'd)

- 10.2019: Bronchoscopy + EBUS (positive in 4L, 10L)
- Brain MRI (11.2019): No CNS metastases
- Staging: Upper left lung squamous cell carcinoma: cT4 (recurrent) cN2 (4L) cM0: stage IIIB (7th and 8th edition)
- PDL1 1%

Case Presentation – Prof Peters: 77-year-old female, former smoker (cont'd)

- Multidisciplinary Tumorboard:

Chemoradiation and consolidation immunotherapy (durvalumab)

- 27.11.2019 au 10.02.2020:

Chemoradiotherapy (60Gy+ carboplatin/vinorelbine: 3 cycles)

1st tumour assessment: CT scan (March 2020)

Desc. examen : CT CERVICO-THORACO-ABD...
< 5 - 150 >

SC : 400.00 mm
159% Pixel
DFOV 46.1 x 40.0 cm
LT 1.00 mm

10 cm

Desc. examen : CT THORACO-ABDOMINAL
< 301 - 84 >

SC : 500.00 mm
159% Pixel
DFOV 42.4 x 36.8 cm
LT 1.25 mm

10 cm

R

R

Case Presentation – Prof Peters: 77-year-old female, former smoker (cont'd)

- 06.04.2020: durvalumab 10mg/kg q2w
- 6 infusions with fatigue grade 1, rash grade 1, cough grade 1, dyspnea grade 2

CT scan: June 2020

Desc. examen : CT THORACO-ABDOMINAL
< 301 - 84 >



Desc. examen : CT THORACO-ABDOMINO-PE...
< 3 - 126 >



Case Presentation – Prof Peters: 77-year-old female, former smoker (cont'd)

- Early July 2020: colitis grade 4, proven by colonoscopy/biopsies
- Prednisone iv 3mg/kg and 2 doses of infliximab iv with slow resolution of diarrhoea and pain
- Durvalumab permanently discontinued
- Symptoms lasting 3 months

CT scan: October 2020

SC: exam1111 : CT CERVICO-THORACO-ABD...
- 150 >



1/0
SC : 400.00 mm
159% Pixel
DFOV 46.1 x 40.0 cm
LT 1.00 mm

10 cm

Desc. exam1111 : CT THORACO-ABDOMINAL
< 2 - 57 >



121
SC : 500.00
159% Pixel
DFOV 44.1 x 38.3
LT 2.50

10

Case Presentation – Prof Peters: 77-year-old female, former smoker (cont'd)

- Bran MRI in December 2023: normal
- CT scan in December 2024: CR

Questions for the Faculty

For patients with resectable localized NSCLC, which strategy do you believe generally offers the best risk-benefit ratio — neoadjuvant, perioperative or adjuvant anti-PD-1/PD-L1 antibody therapy?

How do you currently select among the available neoadjuvant, perioperative and adjuvant immunotherapeutic strategies for individual patients with localized NSCLC in your own practice?

How do you think through the use of neoadjuvant/adjuvant anti-PD-1/PD-L1 antibodies for patients with autoimmune disease or a history of transplant?

Questions for the Faculty

How often do you encounter patients with Stage III NSCLC that is unresectable at initial presentation but might be operable with tumor shrinkage? How do you decide whether to proceed with definitive chemoradiation therapy followed by consolidation durvalumab in these cases versus attempting to downstage the tumor with neoadjuvant immune checkpoint inhibition?

In the absence of an EGFR mutation, are there any situations in which you would NOT employ consolidation durvalumab for a patient with unresectable Stage III NSCLC responding to chemoradiation therapy?

Questions for the Faculty

How would you think through toxicity management in this patient's case? What would you recommend for a patient with low-grade cough and/or dyspnea while receiving consolidation durvalumab?

In patients receiving consolidation durvalumab, how do you differentiate drug-related pneumonitis from other potential causes of symptoms (nonspecific radiation effects on imaging, symptoms from their disease, infection, etc)?

What grade of various immune-related adverse events will prompt you to discontinue therapy with consolidation durvalumab?